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Ageing is associated with impairments in a number of regulatory processes, including in energy 
dysregulation that affects multiple metabolic pathways and in the circadian rhythms. In the management 
of metabolic stress and ageing mechanisms, key proteins such as mTORC, AMPK, and sirtuins are 
known to play an essential role. An impairment in these mechanisms is commonly associated with 
cellular ageing and degenerative diseases. To understand the complex interactions of ageing‐related 
signalling pathways and environmental signals, and the impacts on lifespan and health-span, we 
developed a computational model of metabolic signalling pathways. The model includes (i) the 
insulin/IGF-1 pathway, which couples energy and nutrient abundance to the execution of cell growth and 
division, (ii) mTORC1 and amino acid sensors, (iii) the Preiss-Handler and salvage pathways, which 
regulate the metabolism of NAD+ and the NAD+-consuming factor SIRT1, (iv) the energy sensor 
AMPK, and (v) transcription factors FOXO and PGC-1a. The model can be used as an essential 
component to simulate gene manipulation, therapies (e.g., rapamycin and wortmannin), calorie 
restrictions, and chronic stress, and to assess their functional implications on longevity and ageing‐related 
diseases. 
Another goal of this research project is to unravel the complex interactions among ageing, 
metabolism, and the circadian clock. We seek to identify key factors that inform the liver circadian clock 
of cellular energy status, and to reveal the mechanisms by which variations in food intake may disrupt the 
clock. To address these questions, we develop a comprehensive mathematical model that represents the 
circadian pathway in the mouse liver, together with the insulin/IGF-1 pathway, mTORC1, AMPK, NAD+ 
and the NAD+-consuming factor SIRT1. The model is age-specific and can simulate the liver of a young 
mouse or an aged mouse. Simulation results suggest that the reduced NAD+ and SIRT1 bioavailability 
may explain the shortened circadian period in aged rodents. Importantly, the model identifies the dosing 
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Recent medical advances have dramatically increased life expectancy. By 2050 the world’s population 
aged 60 years and older is expected to total 2 billion, up from 900 million in 2015 (45). However, the 
prevalence of age-related diseases such as cancer, diabetes, and neurodegenerative and cardiovascular 
diseases has risen accordingly. Ageing is a multifactorial process characterized by a gradual decline of 
physiological functions. A series of mechanisms are involved at the molecular, cellular, and tissue levels, 
which include deregulated autophagy, mitochondrial dysfunction, telomere shortening, oxidative stress, 
systemic inflammation, and metabolism dysfunction (149). The dysregulation of these pathways gives 
rise to cellular senescence, which contributes to ageing phenotype and, eventually, age-related diseases. 
However, despite intense research, the molecular basis of the ageing processes has remained incompletely 
understood. The principal goal of this thesis is to utilize mathematical modeling and computer simulations 
to unravel biological processes that contribute to or affected by ageing and ways to stop this process 
which is not generally classified as a disease. 
1.2 Ageing over time 
Achieving immortality or at least increasing lifespan has been one of the greatest challenges facing 
mankind. One can even say the ultimate dream of humankind. This endeavor appears in different forms in 
many cultures and religions. While the symbols or the stories may be different, they all share a common 
theme: Immortality. For example, one of the fundamental and common mythemes in many religions or 
philosophical traditions is the Tree of Life. This tree has been known as a connection between the 
ephemeral life in earth and the source of life. Also, it symbolizes wisdom, strength and beauty (117). 
Various trees of life have been mentioned over time. In the Persian empire, Iranians believed in sacred 
plants related to perpetuity and life. They believed that a tree called Homa was planted by god and 
possessed miraculous curative powers and bestowed the gift of immortality (71). In Chinese mythology, a 
Tree of Life is depicted with a phoenix and a dragon; the dragon often represents immortality and every three 
thousand years the tree produces a fruit which grants immortality to the one who eats it. This concept can be 
found in different religions too. In Islam, there is a tree in Eden called tree of immortality which doesn’t decay. 
It is represented in many artistic paintings or carpets (Quran 14:24). The book of Genesis and the book of 
Revelation address the Tree of Life too; the tree is considered a reward for those who obey the commandments 
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(Revelation 2:7). In the book of Proverbs, the Tree of Life is associated with wisdom and calmness (Proverbs 
3:13-18). In art, the effect of life can be seen in many paintings or movies. For instance, this famous tree can 
be seen in 17th centuries paintings of Iranian artists and in the famous symbolic work of Gustav Klimt in 1909. 
Beside art works, many movies have been made about immortality. In 2006, Darren Arnofsky produced The 
Fountain, which tells a story of a researcher who seeks for a cure for his dying wife. In 2009, Alex Proyas 
directed Knowing, about two young protagonists whose search is toward the Tree of Life.  
Historically, ageing has been thought to be an inevitable process: unless one dies young, one would 
gradually weaken over the years, suffer from more and more age-related diseases, and eventually die. 
However, the distinction between an inevitable process and a (preventable) disease often evolves over time. 
New scientific and technological developments may lead to a reconsideration of these classification and 
switching between those two groups. For example, osteoporosis wasn’t classified as a disease until 1994 by the 
World Health Organization (90). Recently, scientists have started challenging some popular beliefs regarding 
ageing. Should ageing be considered a disease? If so, perhaps efforts can be invested to combat this “disease”. 
For the past 25 years scientists have sought to answer this question by conducting experiments in different 
model organisms such as yeast, flies, rodents, fish and etc. (8). Some of these efforts were successful and it 
was shown that life span can be increased by tenfold in C. elegans and by 60% in killifish (177). These results 
support the idea that ageing should be considered a disease, a concept that has the benefit of potentially 
increasing funding for ageing research studies (29). However, thus far methods which lead to longevity are 
limited to the following: calorie restriction, mimic drugs, gene manipulation, senolytics, stem cells therapy and 
heterochronic parabiosis (14, 82, 193).  
 
1.3 Ageing and metabolism 
The challenges in fully elucidating and, eventually, combating the ageing process may be attributed, in 
part, to the multitude of molecular and cellular processes involved. In particular, the insulin/IGF-1 
(Insulin-like Growth Factor 1) signaling pathway are known to regulate lifespan, and is coupled to the 
mammalian target of rapamycin (mTOR) pathway. mTOR is a highly conserved serine/threonine protein 
kinase that controls cell growth, cell proliferation, cell motility, cell survival, protein and lipid synthesis, 
glucose metabolism, mitochondrial function and transcription in response to nutrient and hormonal 
signals. It is a catalytic subunit of two distinct complexes known as mTORC1 and mTORC2. mTORC2 
consists of mTOR, Rictor (Avo3 homolog) and mLST8, whereas mTORC1 consists of mTOR, Raptor 
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and mLST8 (also known as GβL (197)). The two complexes have different functions. mTORC1 integrates 
information about nutritional abundance and environmental status to balance anabolism and catabolism in 
the cell, while mTORC2 focuses on cytoskeletal behavior and activates several pro-survival pathways, 
especially in caner. 
mTORC1 controls cellular entry into an anabolic state that requires energy and macromolecules, 
which means its activation only occurs when amino acids, insulin/growth factors, ATP and oxygen are all 
available. In the presence of growth factors and insulin, Rheb is GTP loaded and act as a kinase activator 
of mTORC1, but only if mTORC1 is on the lysosomal surface. mTORC1 localization to the lysosomal 
surface in response to nutrient levels, specifically amino acids and glucose is controlled by the active Rag. 
Rag GTPases consist of a constitutive heterodimer of RagA or RagB bound to RagC or RagD (163). 
When there are enough nutrients, RagA/B is GTP loaded and RagC/D is GDP loaded. This active form of 
Rag GTPases promotes the translocation of mTORC1 to the lysosomal surface, where it may come into 
contact with its kinase activator, Rheb in the loaded form. mTORC2 is also regulated by growth factors 
and nutrient availability, and its activation affects insulin signalling pathways, especially AKT. It is not 
clear where mTORC2 activation occurs, however MAPK signalling pathway might recruit mTORC2 to 
the plasma membrane. This interaction between MAPK pathway and mTOR signalling plays a pivotal 
role in cancer which leads to hyperactivation of mTOR signalling up to 80% (116, 187) (Fig. 1). 
mTORC1 protein synthesis process starts by phosphorylating the eukaryotic initiation factor 4E 
(eIF4E)-binding protein 1 (4E-BP1) and the ribosomal S6 kinase 1 (S6K1). The phosphorylation of 4E-
BP1 inhibits its binding to eIF4E, enabling eIF4E to stimulate cap-dependent translation (148). In its 
unphosphorylated state, 4E-BP1 suppresses translation by binding and sequestering eukaryotic translation 
initiation factor 4E (eIF4E), an essential component of the eIF4F cap-binding complex but when 
mTORC1 is in its active form it remains at the mRNA 5′-cap, where it is well positioned to phosphorylate 
4E-BP1 resulting in its dissociation from eIF4E and the recruitment of eIF4G to the 5′-cap, which allows 
cap-dependent translation process to continue (142). 
Moreover, mTORC1 can suppress autophagy inside the cell through phosphorylation of ULK1 
and ATG13, which are the major initiator of catabolism process inside the cell (73). mTORC1 
phosphorylation of ULK1 and ATG13 blocks this process, causing the accumulation rather than the 
recycling of damaged proteins. mTORC1 inhibits autophagosome maturation and the conversion of 
endosomes into lysosomes, thereby acting as a check on both the early and late stages of autophagy (94).  
During periods of starvation or energy stress, the mTORC1 molecular switch is turned off, 
restoring autophagosome initiation and permitting nuclear translocation of both the transcription factor 
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EB (TFEB) and the related transcription factor E3 (TFE3). Then, the new lysosomes break down proteins 
and release amino acids back to the cytoplasm to regenerate the pool of cellular amino acids, enabling 
reactivation of the mTORC1 pathway after starvation. This feedback between mTORC1 activation and 
autophagy by lysosome is essential in conditions including a number of tumors. Similar to mTORC1, 
mTORC2 affects cellular metabolism. It phosphorylates other AGC family kinases, including several 
classes of PKCs (79), the ion transport regulator serum- and glucocorticoid-induced protein kinase 1 
(SGK1) and the Akt (158). This interconnection between AKT and mTORC2 is one of the main 
regulators of cellular metabolism in response to nutrient availability and growth. Within the signaling 
pathway, AKT is located at the nexus of mTORC1 and mTORC2, and can deactive TSC1_TSC2 
inhibition of mTORC1. Moreover, AKT is one of the most frequently mutated signaling nodes in cancer 
cells. AKT also governs the activity of glycogen synthase kinase 3b (GSK3b) to suppress apoptosis and 
modulate glucose homeostasis (110). This suppression of apoptosis is done in another way by AKT. 
Activation of AKT disturbs the balance of cell survival and apoptosis by promoting pro-survival 
transcription factors and inhibiting the FOXO3a pro-apoptotic transcription factor (25). FOXO3a has a 
pivotal role in both oncogenesis and tumor suppression; thus, the inhibition of FOXO30a causes diseases 
and is known as a biomarker of oncogenesis (65). 
Inhibition of this nutrient response pathway extends lifespan in several model organisms and 
ameliorates age-related pathologies. The presence of nutrients and growth factors increases mTORC1 
activity and reduces autophagy initiation, whereas the caloric restriction or inactivation of mTORC1 
increases autophagy contributing to cellular longevity. Insulin/IGF-1 activates mTORC1 by AKT (also 
known as protein kinase B), while mTORC1 inhibits insulin/IGF-1 through S6K by inhibiting insulin 
receptor substrate (IRS). mTORC1 is also regulated by a multitude of amino acid sensors, including the 
sestrin family, the CASTOR family, and the lysosomal amino acid transporter SLC38A9. 
 Also important in the ageing process is the sirtuin family, which consists of highly conserved 
protein deacetylases found nearly in all organisms studied. In mammals, seven silent information 
regulator (SIRT) proteins (SIRT1-7) exist, with SIRT1 being the most extensively studied in the context 
of ageing and is known as one of the main mediators in calorie restriction. SIRT1 senses changes in 
intracellular nicotinamide adenine dinucleotide (NAD+) levels, which reflect energy level, and uses this 
information to adapt the cellular energy output. SIRT1 also enhances DNA repair, cell survival, 
mitochondrial function and reduces ageing inflammatory/immune responses (34). 
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Connecting the sirtuin family to the mTOR pathway is AMPK, a key regulator in energy balance 
in the cells. During periods of cellular energy stress or changes in the ratio between ATP to AMP, AMPK 
is activated and it phosphorylates a number of proteins in various pathways to return the cell to the stable 
condition by favoring catabolism and suppressing anabolism by autophagy. Also, AMPK promotes 
mitochondrial health by promoting mitochondrial fission and biogenesis. One of the mechanisms known 
to reduce cancer growth rate is through AMPK. Its direct phosphorylation of the tumour suppressor TSC2 
and the mTORC1 subunit Raptor blocks mTORC1 from phosphorylating its substrates, thereby 
preventing tumor growth. Furthermore, AMPK has received much attention as a potential target for 
treating metabolic diseases e.g., diabetes. Metformin, a widely used drug for treatment of type 2 diabetes, 
activates AMPK and leads to induction of the expression of glucose transporters (GLUT4), mimicking the 
effects of extensive exercise training. Metformin increases AMPK phosphorylation of acetyl-CoA 
carboxylases, which contributes to changes in lipid synthesis and appears to have a direct impact on 
insulin sensitivity and glucose absorption (205). Additionally, studies on model organisms have revealed 
that mammalian AMPK plays a crucial role in the regulation of lifespan (156). Overexpression of AMPK 
by metformin may extend lifespan in some species, e.g., C. elegans and Drosophila (56). Other studies 
have revealed that the decline in AMPK activation and sensitivity during ageing (147) can activate 
mTORC1 and lead to chronic tissue inflammation. 
 In the past decade, high-throughput genomic and proteomic technologies have generated a wealth 
of data in ageing. Despite the increasing availability of data, some of the molecular mechanisms that 
mediate key ageing effects have yet to be elucidated. The difficulty lies in the complexity of ageing: Not 
only are a large number of genes involved in the ageing process, many with competing roles, but their 
interactions are complex and often incompletely characterized. Indeed, due to the multiple feedback loops 
and regulatory mechanisms, a main challenge in interpreting gene-expression data is to understand the 
biological consequences of gene-expression changes. A promising methodology for interpreting data and 
untangling the interactions among signaling pathways is computational biology. One such approach is to 
describe regulatory interactions using ordinary differential equations (ODEs), which relate changes in the 
expressions of model variables to other quantities. The insulin/IGF-1 pathway has been the subject of 
modeling and analysis by a series of previous studies (3, 4, 39, 40, 101, 132, 133, 166). For instance, 
omics technologies have been applied to investigate the mTOR network (164) and ribosome profiling has 
been used to produce a map of the mTOR targets, which are translationally regulated in different diseases 
(76). Also, In cancer biology and oncology, mathematical models are used to uncover the progression of 
oncogenesis in time and space. That information may be used to identify personalized and precision 
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therapeutics (151). A variety of mathematical methods have been used to model the mTOR signalling 
pathway, including fuzzy logic, ODE, PDEs, and Boolean techniques (15, 170). A Boolean model uses 0 
or 1, respectively, to represent active and inactive forms in biological pathways (182). A fuzzy logic 
model, which considers a range of activity values from 0 to 1, was built by Kriete et al. to study the 
interconnection between mTORC1, ROS and NF-KB in ageing (99). Borisov and colleague showed the 
connection between MAPK and mTOR the two main Signalling pathways in cell growth using ODEs 
(19). In 2016 a mathematical model was proposed by de Pezze and co-workers to investigate the 
connection between AMPK and mTOR signalling pathways (40). 
Unlike the insulin/IGF-1 and mTOR pathways, theoretical effort in modeling the arguably 
equally important regulators NAD+ and SIRT1 is much more limited (an exception is (16)). Thus, in 
Chapter 2 we develop a state-of-the-art computational model that couples these and other critical 
signaling pathways in growth, ageing, metabolism, and disease in mammals. In Chapter 3, we conduct 
model simulations and analyze the interactions among key players in ageing and metabolism: mTORC, 
AMPK, and SIRT1.  A dynamic model of mTOR was proposed to find better therapeutic ways for 
inhibiting mTOR by considering mTOR signaling interaction with Akt. 
1.4 Circadian rhythms and metabolism 
From bacteria to humans, organisms possess a network of molecular reactions and pathways, the 
interactions of which form an internal biological clock, known as a circadian clock, which generates 
biochemical oscillations with a near 24-hour period (46). The mammalian circadian system can be 
divided into two interacting components: the central clock in the suprachiasmatic nucleus (SCN) of the 
hypothalamus and the peripheral clocks that reside in various tissues throughout the body. The peripheral 
clocks play an integral and unique role in each of their respective tissues, driving the circadian expression 
of specific genes involved in a variety of physiological functions. As a whole, the circadian system drives 
daily oscillation in most physiological functions, including circulating hormones (48, 95), cardiac and 
circulatory function (119, 125), and core body temperature (145). The circadian clock can synchronize the 
timing of physiological processes with cyclic changes in the external environment (called “zeitgebers”), 
to the advantage of the organism. Light is a major zeitgeber, especially for the SCN; its importance is 
evinced by the ubiquitous presence of an anticipatory system linking physiology with the light/dark cycle 
in all species. Other key zeitgebers include temperature, food intake, and exercise. Feeding is a 
particularly potent zeitgeber for the peripheral circadian clocks such as the liver clock. 
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  The control of the circadian clock over a variety of cellular and circulating metabolites and fuels 
is well documented. However, that link is more complex than the rhythm simply controlling metabolism. 
Indeed, studies have pointed to a cyclic relationship wherein the rhythm impacts metabolic activity and 
metabolism feeds back to impinge upon the rhythm(152). Perhaps the best test case to evaluate the link 
between metabolism and circadian rhythms is the liver, an organ that is critically involved in the primary 
food response. Cellular metabolism in the liver is markedly affected by changes in feeding status and 
therefore fluctuates as a function of the day/night cycle in rodents (89, 150). To complete the cycle of 
influence, restricted feeding is also known to significantly alter the circadian phase in the liver (42, 169). 
In fact, liver should be considered as one of the main factors in research related to circadian rhythmicity 
and metabolism. As it displays robust oscillations in circadian output genes as well as in genes related to 
the hepatic system (2) especially with metabolism and food intake. Although, SCN lesions generally 
perturb circadian rhythmicity in many organs such as the liver metabolites and strong transcriptional 
activators, such as the glucocorticoid receptor, can return about 60% of rhythmicity to gene expression 
made arrhythmic by SCN lesions (144). 
  Nowadays, there is a dramatic increase in metabolic disorders in a number of societies. This 
unfortunate phenomenon is observed even among children and adolescents due to high fat foods and 
sedentary life style. Not only can zeitgebers affect the circadian clock, they can also perturb our 
metabolism. For example, it has been shown that circadian disturbance, cardiovascular disease, increased 
body mass, and elevated plasma glucose and lipid levels all are common among nighttime shift workers 
(91, 178). Many metabolites that control food intake, including insulin, glucagon, some peptides, 
NAMPT, corticosterone, leptin, and ghrelin, etc. depend on energy status or oscillate in a mostly tissue-
specific circadian manner. Therefore, our feeding and metabolism cycle are affected by the circadian 
clock. Early lesion studies identified the SCN's contribution to circadian rhythmicity in eating and 
drinking. As ablation of the SCN perturbs rhythmicity in both eating and drinking cycle in our body 
(179). SCN in the brain is not the only tissue that can perturb the metabolic cycle (137). Rhythmicity in 
gene expression within tissues is generally unique, in a cell dependent manner. Even the brain itself 
shows tissue-specific oscillations in gene expression, which can be independent of SCN rhythmicity(60). 
Desynchrony between SCN and tissues specific clock rhythm can cause various problems.  
   A concern with this internal and external desynchrony is that the levels of diseases like coronary 
artery diseases like coronary artery disease associated are rising among shift workers (47). To better 
understand the mechanism behind this desynchronization, experiments in rodents have been designed to 
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demonstrate the health difference between night shift workers and the control group. In one study, a 
wheel-running task was imposed on nocturnal rats either during their normal sleep or wake phase. Plasma 
glucose oscillation was lost in rodents that were awake during their sleep phase, and serum triglyceride 
(TAG) levels were reversed from those of control animals, with peaks occurring during the sleep phase 
(155). After a month of sleep-phase work, rats subjected to work during the sleep phase gained more 
weight than controls, supporting human studies that show a similar profile of adiposity and weight gain in 
shift workers. 
  Impairments in circadian rhythms in sleep and behaviors (98) are known to occur in ageing, 
although the underlying mechanisms are not well understood. Ageing is a multifactorial process 
characterized by a gradual decline of physiological functions. A series of mechanisms are involved at the 
molecular, cellular, and tissue levels, which include dysregulated autophagy, mitochondrial dysfunction, 
telomere shortening, oxidative stress, systemic inflammation, and metabolism dysfunction (149). 
Furthermore, ageing is associated with a reduction in the cellular concentration of nicotinamide adenine 
dinucleotide (NAD+), a critical coenzyme for enzymes that fuel reduction-oxidation, and with a decline 
in the expression of SIRT1, a member of the sirtuin family for which NAD+ is a co-substrate, at the 
transcriptional and translational levels. Additionally, ageing is associated with energy deregulation which 
affects many pathways such as pyruvate metabolism, the tricarboxylic acid cycle, and insulin.  
  The interactions among ageing, metabolism, and circadian clock are difficult to unravel. Despite 
the wealth of ageing-related data generated by high-throughput genomic and proteomic technologies, 
some of the molecular mechanisms in these systems have yet to be elucidated. The difficulty lies in the 
complexity of these processes. Previously, models have been developed in order to analyze this complex 
system of interactions inside the cell and try to answer questions related to the circadian clock in our body 
in different specious. These models range from minimal models that can just reproduce one behavior to 
detailed ones that can describe precise mechanisms.  The Goodwin model is the first oscillatory model 
that describes the oscillation based on feedback loops from the clock mRNA to its protein and from the 
repressor to mRNA. This model can produce limit cycle oscillation or damped oscillation based on the 
parameters. Further, new detailed models appeared based on the fact that new pathways, proteins and 
genes related to circadian clock discovered. They use many types of models such as Michaelis-Menten 
equation, Hill function or protein sequestration (140). Since it has been shown that for the Goodwin 
model to produce a limit cycle oscillation the hill coefficient should be above 8 (61). So, it motivated 
many scientists to model this system with other methods (38, 207). In 2003 Goldbeter developed two 
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basic and extended models based on the interconnected negative and positive regulating feedbacks, 
including Bmal1, Clock, Per and Cry genes which one has 16 ODEs and the latter model has 19 ODEs. 
Both models showed the autonomous circadian oscillations of Per and Bmal1 during the night in an 
antiphase manner. Forger and Peskin also proposed a model that contained detailed regulation model of 
the mammalian circadian clock (51). They fitted the model based on optimization methods to find a set of 
parameters for which the model can describe experimental data reported before well. Also, they 
developed another model which was based on stochastic modeling and they compared the behavior of 
deterministic models and the stochastic one (52). They showed in different case scenarios that the 
stochastic model and deterministic model can show different things. For example, one can oscillate while 
the other one doesn’t predict that. There were efforts to reduce the size of the models without losing 
information. Cometa et al. paper can be named as one of these attempts (36). The model developed by 
Forger and Peskin got extended more by Kim and Forger (93) to explain and show more complicated 
processes in the circadian clock pathway.  In 2016 Woller et al. built a mathematical model that contains 
metabolic sensors such as SIRT1, AMPK and circadian clock proteins and genes in liver. 
  In Chapter 4, we present such a model that couples the metabolism model (Chapter 2) to a model 
of core circadian clock genes. In Chapter 5, we conduct model simulations to predict how perturbation in 
one model parameter or variable (or a set of parameters and variables), can affect other variables and 






Mathematical Model of Metabolic Pathways 
2.1 Introduction 
In this chapter we present a comprehensive model that includes (i) the insulin/IGF-1 pathway, which 
couples energy and nutrient abundance to the execution of cell growth and division, (ii) mTORC1 and the 
amino acid (AA) sensors, (iii) the Preiss-Handler and salvage pathways, which regulate the metabolism of 
NAD+ and the NAD+-consuming factor SIRT1, (iv) the energy sensor adenosine monophosphate-
activated protein kinase (AMPK), and (v) transcription factors forkhead box O (FOXO) and peroxisome 
proliferator-activated receptor gamma coactivator 1-a (PGC-1a), the overexpression or mutation of 
which affects lifespan. In the next chapter, we apply the model to investigate the synergy among 
regulators of nutrients, energy, metabolism, and autophagy, and to identify novel therapeutic targets. 
The model can be used to aid in the interpretation of genomic and proteomic data, and to provide an 
integrated understanding of the mechanisms that lead the cell to senescence and how this process 
contributes to metabolic disorders and age-related diseases.  
2.2 Model description 
Main model components include the insulin/IGF-1 or mTOR signaling pathway (103), the Preiss-Handler 
and salvage pathways (43), energy sensor AMPK, and transcription factor FOXO and PGC-1a, in the 
mouse C2C12 cell. The dynamics of the signaling pathways is modeled as a system of ODEs; Figs. 1 and 
A1 depict the pathways and protein interactions. The reactions and associated parameters are presented in 
Table S1 and the Excel file. Model parameters are taken from published studies which were able to 
capture the biochemical interaction rates (16, 40, 192) and fitted to experimental data (39, 109, 135, 165, 
192) using the interior point optimization method in fmincon() in MATLAB, with parameter ranges set to 






Figure 1. Pathway representation of network model, some components of which may be activated by 
amino acids, such as leucine (blue circles) and arginine (red circles), and insulin (green triangles0. The 
model represents three distinct areas in the cell: the cytoplasm, lysosome, and the nucleus. 
 
Within the insulin/IGF-1 signaling and mTOR pathways, insulin activates the insulin receptor 
(IR), which triggers the IRS and PI3K, resulting in the phosphorylation of PDK1 and mTORC2, 
respectively. mTORC2 phosphorylates AKT on the S473 and T308 residues, whereas PDK1 activates 
AKT. Active AKT phosphorylates a variety of proteins, including FOXOs, TSC1_TSC2 and PRAS40. 
Phosphorylation of TSC1_TSC2 by AKT inactivates the TSC complex, thereby activating mTORC1 and 
resulting in a number of downstream effects. These include (i) inhibition of ULK1 by phosphorylating 
ULK1 on Ser 757; the ULK1 complex is a key contributor to the initiation of autophagy; (ii) 
phosphorylation of PRAS40, which attenuates the inhibition of mTORC1; (iii) phosphorylation of 
p70S6K on T229 and T389, which initiates a negative feedback loop via IRS.  
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An important novel aspect of our model is the explicit representation of the role of sestrin2 and 
leucine in the regulation of mTORC1. Sestrin2 deactivates mTORC1, via its effects on protein complexes 
GATOR1 and GATOR2. GATOR1 inhibits mTORC1, whereas GATOR2 inhibits GATOR1. Sestrin2 
inhibits GATOR2, enhancing the activation of GATOR1, and eventually suppressing mTORC1. This 
process is modulated by leucine, which binds to sestrin2 and impeding its inhibitory effect on mTORC1 
(187). Thus, mTORC1 activation depends, among other factors, on the concentration of sestrin2 and 




= −𝑘TSC[mTORC1_pS2448]([TSC1_TSC2] + [TSC1_TSC2_pS1387])
+ 𝑘AA[mTORC1!"!][AA] 2
𝑉max([L] + 𝑐LS)
[S] + [L] + 𝑐LS
5 − 𝑓#([PRAS40]) − 𝑓$([Act ULK1]) 
            (1) 
where [AA], [L], and [S] denote the amino acid, leucine, and sestrin2 concentrations, respectively; and 
mTORC1tot denotes total mTORC1. Act ULK1 denotes the activated form of ULK1. The first term on the 
right describes the inhibition of mTORC1 by the TSC1_TSC2 complexes; the second term describes the 
effects of leucine and sestrin2 on mTORC1; the third and fourth terms describe the contributions from 
PRAS40 and activated ULK1. respectively. The expression for 𝑓1	and 𝑓2	can be found in the Appendix. 
The model simulates the dynamics of another key player in metabolism, NAD+, which is 
produced through the de novo, Preiss-Handler and salvage pathways. The major source of NAD+ in 
mammals is the salvage pathway, which recycles NAM produced by enzymes utilizing NAD+. The first 
step in the salvage pathway involves the rate-limiting enzyme NAMPT, which facilitates the conversion 
of NAM to NMN and whose activity is increased by AMPK, and the expression and/or activity of which 
when reduced is associated with ageing and poor health. (81) The second step converts NMN to NAD+ 
via the NMNAT enzymatic reaction. NAD+ thus produced activates substrates including SIRT1 and is 
consumed in the process. Albeit less important for NAD+ biosynthesis in mammals, the Preiss-Handler 
pathway is also represented. The pathway begins with the conversion of NAM to NA, followed by the 
conversion to NAMN, catalyzed respectively by NADA and NAPRT. Like the salvage pathway, NMNAT 
in Preiss-Handler pathway also catalyzes the process of production of NAAD from NAMN. Finally, the 
reamidation of NAAD by NADS yields NAD+. The Preiss-Handler pathway is more energy and ATP 
consuming than the salvage pathway.  
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Connecting the mTORC1 and NAD+ pathways is AMPK, a master regulator of cellular energy 
that is activated under starvation or hypoxia. AMPK can be stimulated by sestrin, IRS, and liver kinase 
B1 (LKB1) which deacetylated by SIRT1. Activated AMPK promotes autophagy by directly 
phosphorylating and activating ULK1. As such, there is a competition between mTORC1 and AMPK to 
phosphorylate different residues of ULK1 to decide cells fate. ULK1 in turn inhibits AMPK and 
mTORC1 in a negative feedback loop, whereas leucine activates them. 
Therapeutic treatments and dietary conditions are simulated by changing selected model 
parameters (see below). For a given set of parameters, a steady-state solution can be computed by 
integrated the model equations for a sufficiently long time. For simulations that involve a change in 
model parameters, model variables are initialized to the steady-state solution corresponding to the 
parameter values at the initial time. Such initial conditions are realistic and avoid an abrupt change in 








Interactions among mTORC, AMPK, and SIRT: A Computational 
Model for Cell Energy Balance and Metabolism 
3.1 Introduction 
In Chapter 2 we describe a state-of-the-art computational model for investigating signaling pathways in 
growth, ageing, metabolism, and disease in mammals. Major model components include the insulin/IGF-
1 or mTOR signaling pathway (103), the Preiss-Handler and salvage pathways (43), energy sensor 
AMPK, and transcription factors FOXO and PGC-1a. The mTOR signaling pathway couples energy and 
nutrient abundance to the execution of cell growth and division, whereas the Preiss-Handler and salvage 
pathways regulate the metabolism of NAD+ as well as NAD+-consuming proteins such as sirtuins.  
In this chapter, we conduct model simulations to (1) compare different means of 
pharmacologically suppressing mTORC1, often done to control tumor growth, (2) interrogate the 
interplay between amino acid leucine and its sensor, sestrin2, and the effect on mTORC1 activity, (3) 
analyze the interactions between arginine and leucine during protein deprivation, which predicts a signal 
that reactivates mTORC1 and downregulates autophagy, and (4) examine the pharmacological activation 
of SIRT1 and its regulation of autophagy.  
 
3.2 Pharmacological suppression of mTORC1.  
Given the role of mTORC1 in metabolic diseases, there is great interest in developing drugs to suppress 
this enzyme. Rapamycin, a potent and selective inhibitor of mTORC1, has emerged as an FDA-approved 
immunosuppressant and anti-cancer agent. We conduct simulations to investigate the molecular 
mechanisms underlying the effects of rapamycin and its interactions with other mTORC1 inhibitors (87).  
How do nutritional levels affect the actions of mTORC1 inhibitors? Because hyperactivation of 
mTORC1 disrupts cellular homeostasis, mTORC1 is regulated by a number of mechanisms, some of 
which are included in the present model. Both TSC1_TSC2 and its S1387-phosphorylated form 
deactivate mTORC1, as does the (dephosphorylated) proline-rich AKT substrate of 40 kDa (PRAS40). 
Compared to TSC1_TSC2, the regulation by PRAS40 of mTORC1 is less well studied; in fact, PRAS40’s 
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effect on mTORC1 was not represented in a recent detailed mTORC pathway model (40). Located at the 
crossroad of the insulin/IGF-1 pathway, PRAS40 is phosphorylated by growth factors or other stimuli, 
and in turn regulates the activation of these signaling pathways. PRAS40 plays an important role in 
metabolic disorders and multiple cancers, and is known to be an insulin-regulated inhibitor of mTORC1 
(157). To assess how that regulation is altered by nutritional levels and pharmacological interventions, we 
develop the first metabolism model that includes the actions of PRAS40. In these simulations, the model 
is initialized at the fasting state with a low insulin level (10% of baseline level). At t = 40 min, insulin 
level is returned to baseline and maintained at that level.  
The inhibitory effect of PRAS40 is contingent on the nutritional level. With sufficient insulin and 
no drug treatment (i.e., control; administration of rapamycin will be considered below), PRAS40 
inhibition of mTORC1 has only a minor impact on mTORC1, lowering its steady-state phosphorylated 
level by 18% (compare Fig. 2a, left and right panels, black curves, t > 40 min). The effects of PRAS40 on 
other proteins are similarly minor (Figs. 3 and 4). In contrast, at low insulin level, PRAS40 inhibition of 
mTORC1 results in a substantially lower phosphorylated mTORC1 level (1.00 versus 3.94; compare Fig. 
2a panels, black curves, t < 40 min). A lower insulin level decreases AKT_pT308_S473 (Fig. 3b) and 
thus phosphorylated mTORC1; both changes reduce the phosphorylation rate of PRAS40 (Fig. 2c). The 
resulting higher unphosphorylated PRAS40 level reduces mTORC1 phosphorylation rate. The predicted 
profiles are consistent with experimental data in (40), measured by the L2 norm of the difference between 











Figure 2. Effects of insulin, rapamycin, and wortmannin on key proteins and their interactions. Insulin was 
lowered to 10% of its baseline level for the initial 40 min of the simulation, and subsequently returned to 
baseline level. Simulations are conducted for control, acute and chronic administration of rapamycin, 
chronic administration of rapamycin with wortmannin. The inhibition of PRAS40 of mTORC1 is 
represented in the left panels but not the right ones. Model predicts that PRAS40 substantially lowers 
mTORC1 level under low insulin conditions. That effect is the most prominent under chronic 




Figure 3. Effects of insulin, rapamycin, and wortmannin on key proteins and their interactions. Notations 




Figure 4. Effects of insulin, rapamycin, and wortmannin on key proteins and their interactions. Insulin 
was lowered to 10% of its baseline level for the initial 40 min of the simulation, and subsequently 
returned to baseline level. Simulations are conducted for control, acute and chronic administration of 
rapamycin, chronic administration of rapamycin with wortmannin. The inhibition of PRAS40 of 
mTORC1 is represented in the left panels but not the right ones. Model predicts that PRAS40 
substantially lowers mTORC1 level under low insulin conditions. That effect is the most prominent under 
chronic administration of rapamycin and wortmannin. 
 
What are the factors that affect the effectiveness of rapamycin, an mTORC1 inhibitor and anti-
cancer agent? We consider both acute and chronic administration of rapamycin. Acute administration of 
rapamycin is simulated by decreasing total mTORC1 by 75% (162). With chronic rapamycin 
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administration, mTORC2 is targeted in addition to mTORC1 (102); thus, chronic administration is 
simulated by decreasing both mTORC1 and mTORC2 by 75%. We seek to answer the question: Do 
rapamycin and PRAS40, both of which inhibit mTORC1, interact and produce nonlinear effects? One 
might expect that together, rapamycin and PRAS40 may produce more than the sum of individual effects. 
This is because rapamycin lowers activated mTORC1 level and, as a result, decreases the phosphorylation 
of PRAS40 to PRAS40_pS183. Taken in isolation, that would increase dephosphorylated PRAS40 and 
further inactivate mTORC1. To assess the validity of that hypothesis, we simulate the administration of 
rapamycin with and without PRAS40 regulation. Model simulations predict that, following acute and 
chronic administration of rapamycin, mTORC1 level decreases by about 75% from its control level (Fig. 
2(a,b)), which suggests limited super-additive effect arising from any interactions between rapamycin and 
PRAS40.  
 
Why doesn’t PRAS40 augment the inhibitory effect of rapamycin? As noted above, the lower 
phosphorylated mTORC1 level, taken in isolation, would increase dephosphorylated PRAS40. However, 
through a feedback mechanism, the lower phosphorylated mTORC1 level also decreases p70S6K_pT389, 
increases phosphorylated IRS and phosphorylated PI3K_PDK1, and eventually, increases AKT_pT308 
and AKT_pT308_pS473, both of which increase the phosphorylation of PRAS40 to PRAS40_pT246. The 
competing effects on PRAS40 phosphorylation results in negligible change in unphosphorylated PRAS40 
level. 
Following chronic rapamycin administration, the lower phosphorylated mTORC2 level slows the 
phosphorylation of AKT to AKT_pS473, reducing both AKT_pS473 and the downstream 
AKT_pT308_pS473 (Fig. 3(a,b)). Taken in isolation, these effects, together with the reduced 
phosphorylated mTORC1, would slow the phosphorylation of PRAS40 and increase dephosphorylated 
PRAS40 level. But in a competing effect, the lower phosphorylated mTORC1 level increases 
AKT_pT308, which increases the phosphorylation of PRAS40 to PRAS40_pT246. These competing 
effects together yield negligible change in unphosphorylated PRAS40 level (Fig. 2c). Therefore, acute or 
chronic administration of rapamycin alone does not significantly alter PRAS40 levels. 
 
 How can we augment the inhibition of mTORC1 by rapamycin, especially at high insulin level? 
We hypothesize that this be achieved by pharmacological manipulations that elevate PRAS40. To identify 
an effective compound, we note that in addition to mTORC1, PRAS40 is also phosphorylated by AKT. 
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This motivates us to consider inhibitors of PI3K_PDK1, which phosphorylate and activates AKT. We 
simulate such an inhibitor, wortmannin, by lowering total PI3K_PDK1 by 80% (26). 
A noticeable effect can be observed in PRAS40 when wortmannin is combined with chronic 
rapamycin administration. The lower phosphorylated PI3K_PDK1 level decreases AKT_pT308 and 
AKT_pT308_pS473, slowing the phosphorylation of PRAS40 to PRAS40_pT246. Together with reduced 
phosphorylated mTORC1, this maneuver substantially increases unphosphorylated PRAS40 at baseline 
insulin by 55% (Fig. 2c, left). The elevated PRAS40 substantially suppresses mTORC1_pS2448 (Fig. 2a, 
left). Analogous effects are also obtained for MK-2206, an allosteric inhibitor of AKT.  
 
 
Figure 5. Effect of rapamycin on glucose tolerance. Glucose tolerance test begins at t = 40 min. 
Normalized plasma glucose profiles are obtained for acute rapamycin administration, and for chronic 
rapamycin administration at different dosages, with and without wortmannin. Vehicle data from (5). 
 
 Optimizing rapamycin dosage to maintain insulin sensitivity while preserving mTORC1 
inhibition. Whereas acute treatment with rapamycin prevents nutrient-induced insulin resistance, the 
chronic administration of rapamycin may lead to glucose intolerance. This adverse side-effect is 
attributable to the inhibition of mTORC2 by chronic rapamycin treatment, resulting in the attenuation of 
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AKT_pT308_pS473, which is essential in the translocation of GLUT4 (53, 74). In the next set of 
simulations, we explore the possibility that an optimal rapamycin dosage may be determined that 
attenuates its detrimental effect on insulin sensitivity while preserving its inhibition of mTORC1. To 
accomplish that goal, we simulate the glucose tolerance test and track plasma glucose concentration by 
𝑑[𝐺]
𝑑𝑡
= 	𝑘(,*+	–	𝑘(, -!.	[𝐺][AKT_pT308_pS472]																																																																								(2) 
 
The cellular uptake rate of plasma glucose is assumed to be proportional to the cellular concentration of 
AKT_pT308_pS472. As in the previous simulations, the model is initialized at the fasting state with a low 
insulin level, glucose = 1, and 𝑘(,*+ = 0 which represents the absence of glucose intake; 
additionally,	𝑘(, -!.	 = 7×10-4/min. At t = 40 min, the glucose tolerance test begins, whereby plasma 
glucose is elevated by setting 𝑘(,*+ to 0.115/min at t = 40 min then linearly decreases to 0 in the next 25 
minutes. Additionally, insulin is proportional to plasma glucose.  
 
We simulate the glucose tolerance test under four conditions: control, acute rapamycin 
administration, chronic rapamycin administration, and chronic rapamycin and wortmannin administration 
(parameters as described in previous simulations). For chronic rapamycin, we considered mTORC2 
inhibition at 75% (baseline), but also at 65%, 50%, and 25%, with mTORC1 inhibition fixed at 75%. 
The predicted plasma glucose time-course profiles are shown in Fig. 5, together with experiment 
data obtained for vehicle (5). Acute rapamycin usage inhibits mTORC1 (but not mTORC2), which 
suppresses p70S6K_pT389, increases phosphorylated IRS, AKT_pT308 and AKT_pT308_pS473, 
thereby improving insulin sensitivity. In contrast, chronic rapamycin usage inhibits mTORC2 as well. 
That lowers AKT_pS473 and AKT_pT308_pS473, and, at sufficiently high dosage (>50% mTORC2 
inhibition), leads to impaired glucose tolerance. If wortmannin is added, AKT_pT308_pS473 is further 
suppressed, resulting in a sustained elevated plasma glucose level. 
Findings in PC3 cells (prostate cancer cells) suggest that differing rapamycin dosages may yield 
near maximal mTORC1 inhibition with a range of mTORC2 inhibition levels (162). Model simulations 
suggest that lowering rapamycin-induced mTORC2 inhibition from 75% (baseline) to 50% restores 
insulin sensitivity to control level, consistent with intermittent administration of rapamycin (6, 102). If it 
is possible to further reduce mTORC2 inhibition to 25% while preserving mTORC1 inhibition at 75%, 
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one even achieves an improvement in insulin sensitivity, due to the beneficial effect of mTORC1 
inhibition overriding the impairment arising from the (attenuated) mTORC2 inhibition. 
 
3.3 Amino acid sensors and mTORC1 regulation. 
As noted above, hyperactivation of the mTORC1 is implicated in the pathogenesis of cancer and other 
ageing-related diseases. mTORC1 promotes growth in response to the availability of nutrients, such as 
amino acids, which drive mTORC1 to the lysosomal surface, its site of activation. Among the twenty 
classical L-amino acids, arginine and leucine are two essential amino acids that potently stimulate the 
activity of mTORC1. However, aspects of the molecular mechanisms by which these specific amino acids 
stimulate mTORC1 activity remain to be completely understood. Thus, in a set of simulations, we 
examine the roles of these amino acid sensors in mTORC1 regulation. 
 
We first investigate the regulation of mTORC1 by leucine and its sensor, sestrin2. Sestrin2 and 
leucine exert opposite effect on mTORC1, with sestrin2 deactivating mTORC1, and leucine increasing 
mTORC1 activity by binding to sestrin2. To investigate the dependence of mTORC1 activation level on 
leucine and sestrin2, we consider the steady-state formulation of Eq. 1 (by setting the time-derivative to 






[S] + [L] + 𝑐LS
,
𝑘TSC([TSC1_TSC2] + [TSC1_TSC2_pS1387]) + 𝑘AA[AA]
𝑉max([L] + 𝑐LS)
[S] + [L] + 𝑐LS




The regulation of mTORC1 activity by leucine and sestrin2 is shown in Fig. 6(a,b), by evaluating 
Eq. 3 for given AA and TSC1_TSC2 complex levels. Consider the system with a typical lysosomal 
leucine concentration. At a sufficiently low sestrin2 concentration, GATOR2 is activated, GATOR1 is 
inhibited, and mTORC1 activation rate is maximized. Conversely, at sufficiently high sestrin2 
concentration, mTORC1 is rapidly dephosphorylated. Also, for a fixed sestrin2 concentration, increasing 
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the concentration of leucine raises the phosphorylation rate of mTORC1. Now for a typical sestrin2 
concentration, Fig. 6a exhibits the Michaelis-Menten-like dependence of mTORC1 activity on leucine.  
Figure 6. mTORC1 activity as a function of normalized leucine and sestrin concentrations, and model 
response to protein depletion and restoration. Panel a, mTORC1 activity for differing sestrin levels. Panel 
b, mTORC1 activity for the full range of leucine and sestrin concentrations. Predicted levels of 
mTORC1_pS2448 (c), p70S6K_pT389 (d), activated ULK1 (e), and AMPK_pT172 (f) under amino acid 
depletion (t < 2 h) and restoration (t > 2h), obtained for differing sestrin levels. 
 
Sestrin has been found to induce autophagy during diverse environmental stresses that provoke 
mitochondrial dysfunction (111), through AMPK activation and mTORC1 inhibition. Specifically, after 
leucine binds to sestrin2, the resulting complex activates AMPK. Thus, the model assumes that AMPK 
phosphorylation rate is proportional to the concentration product [Leucine][Sestrin] (27). How does the 
interaction between sestrin2 and AAs affect the dynamics of AMPK activation, mTORC1 inhibition, and 
autophagy stimulation? To answer that question, we conduct simulations in which AA levels (including 
leucine) are initially set to 10% of baseline values, then subsequently increased to baseline levels. 










Figure 7. Effect of protein depletion and restoration on key model variables, obtained for differing 
sestrin2 levels. 
Key model variables are exhibited in Figs. 6 and 7. Time profiles of mTORC1_S2448 and 
p70S6K_pT389 approximate that of AAs, whereas activated ULK1 exhibits the opposite trend. As 
sestrin2 concentration decreases, the activating effect of AAs on mTORC1 and p70S6K is enhanced (Fig. 
6(c,d)), as is their inhibition of ULK1 and autophagy (Fig. 6e). AAs have competing effects on the 
phosphorylation of AMPK. Leucine and sestrin2 together activate AMPK directly. In addition, through 
mTORC1 and its inhibition of IRS_p, AAs inhibit AMPK. The model predicts that the latter (inhibition) 
dominates, resulting in the activation of AMPK when proteins are depleted, consistent with experimental 
observations (37). The inhibition of AMPK by AAs is modulated by sestrin2 (Fig. 6f). The model predicts 
that the latter (inhibition) dominates, resulting in the activation of AMPK when proteins are depleted; this 
result is consistent with experimental observations (37).
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 The next set of simulations, we focus on the modulation of mTORC1 by two major amino acid 
regulators, arginine and leucine. During AA starvation, lysosomal AAs (leucine in particular) facilitate 
mTORC1 activation. The transfer of lysosomal leucine to cytoplasm is mediated by SLC38A9, an 
arginine-regulated AA transporter (88). We first determine how that transfer process varies as a function 
of lysosomal amino acid content. Wyant et al. reported that arginine enhances the capacity of SLC38A9 
to transport leucine, by increasing its Vmax without significantly affecting its Km (192). Taking both 
leucine and arginine into account, we model leucine transport rate, denoted Vmax,L, as 
𝑉max,L = 𝑉max,L∗ ([𝐴] + 𝑐0) E
[2]
4!,#5[2]
F                                                                                   (4) 
where cA denotes the contribution of lysine, which also transports leucine albeit significantly less 
effectively than arginine. In the absence of either AA groups ([A] + cA = 0 or [L] = 0), there is no leucine 
efflux. Under basal conditions, the concentration of lysine is sufficiently low that cA is taken to 0. The 
resulting leucine efflux, determined for a range of lysosomal leucine and arginine concentrations (187), is 
shown in Fig. 8(a,b). The predicted leucine transport rate at basal and +200 µM arginine profiles are 
consistent with measurements reported by Wyant et al. (192) (Fig. 8a). 
 To assess the role of arginine in the regulation of mTORC1 and autophagy during AA depletion, 
we conducted simulations in which cytoplasmic AA progressively decreases during the first 3 hours; 
afterwards, lysosomal AAs are released (200). We simulate high, medium, low, and zero arginine levels 
by varying the rate at which cytoplasmic AA increases due to lysosomal leucine efflux. In the presence of 
insulin, AAs activate mTORC1, which inhibits autophagy by phosphorylating ULK1 (92). Upon AA 
depletion, mTORC1 activation on the lysosomal surface is no longer maintained (Fig. 8c). Consequently, 
ULK1 Ser757 is rapidly dephosphorylated (Fig. 8d) (92), resulting in activation of the ULK1 kinase and 
concomitant autophagy induction. A similar trend is observed for AMPK (Fig. 8e). 5e) (92), resulting in 
activation of the ULK1 kinase and concomitant autophagy induction. When cytoplasmic AAs are 
sufficiently depleted, leucine is transported out of the lysosome by arginine-stimulated SLC38A9, 
activating mTORC1, phosphorylating p70S6K and ULK1, and suppressing autophagy (Fig. 8(c,d)). 





Figure 8. Leucine transport rate as a function of leucine and arginine concentrations, and its effect on 
mTORC1 reactivation. Panel a, leucine transport rate is computed with arginine concentration taken to be 
50 µM (“Starvation”), 175 µM (“Vehicle”), 375 µM (“+200 µM Arginine”), 575 µM (“+400 µM 
Arginine”). Data taken from (192). Panel b, leucine transport rate shown for the full range of leucine and 
arginine concentrations. Predicted levels of mTORC1 pS2448 (c), activated ULK1 (d), and 










Figure 9. Effect of protein deprivation and subsequent leucine efflux on key model variables, obtained 












3.4 Pharmacological activation of SIRT1. 
Resveratrol, a SIRT1 activator, mimics the anti-ageing effects of calorie restriction in lower organisms 
and mice, and leads to improved exercise performance and insulin sensitivity (75). Other SIRT1-
activating compounds (STACs) have been identified that are structurally unrelated to and more potent 
than resveratrol (75). In the next set of simulations, we seek to unravel the metabolic molecular processes 
that give rise to both the health benefits and potential side effects of STACs. 
 
STACs and their anti-ageing effects. We compare the effects of resveratrol to three other STACs: 
SRT2183, SRT1460, and SRT1720. We assume that the STACs alter the Michaelis constant in the 
dependence of SIRT activity on its substrates (135). Based on in vitro findings by Milne et al. at 10 µM, 
resveratrol reduces baseline substrate Km by 20%, SRT2183 by 50%, SRT1460 by 60%, and SRT1720 by 
70% (figure 2a in Ref. (120)). As shown in Fig. 11a, at baseline Km of [NAD+] = 0.029 mM, resveratrol 
slightly enhances SIRT1 activity by 11%. Other STACs has larger effects; SRT2183 elevates SIRT 
activity by 29%, SRT1460 by 43%, and SRT1720 by 54%.   
As shown in Fig. 11a, the STACs increase SIRT activities to different degrees. SIRT regulates 
transcription by deacetylating transcription factors FOXO (112). The deacetylation rate of FOXO is 
described by Michaelis-Menten kinetics (31). Model predicts that all STACs increase FOXO 
deacetylation but to significantly different degrees (Fig. 11b). At baseline Km of [FOXO] = 141µm (31), 
resveratrol increases FOXO deacetylation rate by a moderate degree (11%). Other STACs are more 
effective, with the largest increase obtained for SRT1720 (54%).   
 STACS activate AMPK and SIRT1, leading to the deacetylation of peroxisome proliferator-
activated receptor-γ coactivator 1-α (PGC-1α). Similar to FOXO, the deacetylation rate of PGC-1α is also 
described by Michaelis-Menten kinetics (31).  PGC-1α activation improves mitochondrial biogenesis. At 
baseline PGC-1α Km level, resveratrol increases PGC-1α deacetylation rate by 12%. Larger improvements 





Figure 11. STACs activate SIRT1 (normalized values shown) by lowering the Michaelis-Menten 
constant for NAD+ (panel a). The deacetylation rates of FOXO and PGC-1a are subsequently affected 




Figure 12. Predicted effects of STACs on SIRT1 activity (panel a), AMPK_pT172 (b), NAMPT (c), 
NAD+ (d), mTORC1_pS2448 (e), and activated ULK1 (f). Values are shown relative to control. 
 
The effects of these compounds on key protein activities are shown in Fig. 12. Consistent with 
results in Fig. 11a, STACs raise SIRT1 levels, by as much as 32% (SRT1720; Fig. 12a). SIRT1 in turn 
activates AMPK, although the SIRT1-induced increase in AMPK_pT172 is relatively small compared to 
SIRT1 (Fig. 12b).  
AMPK regulates nicotinamide phosphoribosyl transferase (NAMPT) (23), which acts as a 
limiting enzyme in the conversion of NAM to nicotinamide mononucleotide (NMN). Taken in isolation, 
the STAC-induced elevation in NAMPT (Fig. 12c) would accelerate the conversion of nicotinamide 
(NAM) to NMN, resulting in an increase in the downstream NAD+. However, the STACs also accelerate 
the consumption of NAD+ by binding on the allosteric site of SIRT1. Indeed, the enhanced SIRT1 
consumption is the stronger effect, resulting in lower NAD+ following the administration of STACs (Fig. 
12d), by as much as 56% with SRT1720. 
The present model is based on C2C12 cells, in which AMPK does not regulate mTORC1 directly 
but instead facilitates the phosphorylation of TSC1_TSC2 at ser S1387 (39). Because both TSC1_TSC2 
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and its phosphorylated form TSC1_TSC2_pS1387 deactivate mTORC1, AMPK has a negligible effect on 
mTORC1 inhibition. AMPK regulates autophagy through direct phosphorylation of ULK1 (92). Thus, 
despite mTORC1’s insensitivity to STACs, the level of activated ULK1 is predicted to be increased by 
STACs (Fig. 12f). 
 
Figure 13. Potential overactivation of autophagy by STACs at high nutrient level. a, normalized levels of 
AMPK_pT172 obtained for control (“Vehicle”), for SRT1720, where SIRT1 substrate Km is reduced by 
70%, and for a hypothetical STAC where Km is reduced by 90% (“SRTx”). For each case, AMPK_pT172 
levels are determined at an AA level is 25% of control (“Low AA”) and for reference AA conditions 
(“High AA”). b, normalized levels of mTORC1_pS2448. c, activated ULK1. With a sufficiently strong 
STAC (“SRTx” and “High AA”), autophagy may be activated at a level close to that at AA deprivation 




Given that STACs enhance AMPK and ULK1, we investigate the following possibility: Can 
STAC intake lead to premature autophagy, i.e., protein catabolism under an abundance of nutrients? The 
inhibitory phosphorylation of ULK1 by mTORC1 serves as a negative feedback to prevent overactive 
autophagy and to avoid a futile cycle in which newly synthesized cellular building blocks are prematurely 
broken down again. But is this safeguard sufficient under the actions of STACs? To answer these 
questions, we consider three groups: control, SRT1720, and a (hypothetical) higher-performing STAC 
(called “SRTx”) which we assume reduces substrate Km by 90%. Simulations are conducted for baseline 
AA level, and a low AA level that is 25% of baseline. Predicted AMPK_pT172, mTORC1_pS2448, and 
ULK1 activation levels are shown in Fig. 13. STAC and AA both increase AMPK_pT172, whereas 
mTORC1_pS288 is substantially elevated by AA, but is relatively insensitive to STAC. ULK1 is 
activated by AMPK (Fig. 1), and thus simulations predict that STAC increases activated ULK1 level. In 
contrast, ULK1 is inhibited by mTORC1, and thus AA abundance is predicted to suppress ULK1. 
Simulation results indicate that, with abundance of nutrients, SRTx yields ULK1 activation level that is 
91% of the analogous level obtained for the control group under AA deprivation. The similar autophagy 
activation under these two sets of conditions, despite the widely differing AA abundance levels, suggests 
that a sufficiently potent STAC may induce premature autophagy (110). 
 
3.5 Parameter sensitivity analysis. 
We perform local sensitivity analysis to assess the response of model outputs to small variations in 
selected parameter values (Fig. 14). Sensitivity of model output x to a parameter p is given by the relative 





                                                                                (5) 
where in our computations, ∆𝑝 = 0.01	𝑝. Other parameters are fixed and all model outputs are updated 
simultaneously when p is varied. 
Two distinguishable heat-map regions are identified with mostly non-zero entries. These regions 
are associated with the original model components: the insulin/IGF-1 signaling pathway (top-left region) 
and the Preiss-Handler and salvage signaling pathways (bottom-right region). These two components are 
coupled via the effects of AMPK on NAMPT, and of SIRT on AMPK. Variations in parameters in one 




Figure 14. Heat map that illustrates the sensitivity of key model outputs (horizontal axis) to local 
variations in selected model parameters (vertical axis). Definition of the parameters can be found in the 
Supplemental Materials. 
 
 Within the insulin/IGF-1 signaling pathway, model outputs are particularly sensitive to variations 
in links that activate or inhibit proteins that have a large number of downstream effects. E.g., the 
activation of IRS_p by p70S6K_pT229_pT389 (“par_IRS_phos_by_p70_S6K_pT229_pT389”). Except 
for mTORC2_pS2481, other outputs in the insulin/IGF-1 signaling pathway exhibit significant sensitivity 
to variations in that activation strength, because IRS_p directly modulates major model variables such as 
PI3K_PDK1 and AMPK. In contrast, model solution is insensitive to changes in the activation of 
IRS_pS636 by p70S6K_pT229_pT389, in large part because the IRS_pS636 has no direct downstream 
effect. 
 Within the Preiss-Handler and salvage signaling pathways, most model outputs exhibit significant 
sensitivity to variations in the selected parameters associated with the pathways. NAM exhibits 
remarkable stability, because of the robust negative feedback cycle involves itself, NMN, NAD+, and 
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SIRT1. Proteins in this pathway are particularly sensitive to changes in the abundance of active NAMPT 
(“Kcat_NAMPT”). This result suggests that an NAMPT activator may be a promising pharmacological 





Mathematical Model of Circadian Clock 
4.1 Introduction 
In this chapter we present a state-of-the-art computational model that couples the metabolism and 
circadian pathways, to investigate the roles of these pathways in ageing and metabolism in mammals. We 
aim to apply the model to answer important questions: What are the key factors that advice the liver 
circadian clock about the cellular nutritional state, and facilitate its entrainment to a feeding schedule? 
How might variations in daily food intake or nutritional stress disrupt the clock? How do those processes 
change as one ages? What time of day should one take an anti-ageing medication to maximize its 
efficacy? To address these questions, we present a comprehensive model that includes (i) the insulin/IGF-
1 pathway, which couples energy and nutrient abundance to the execution of cell growth and division, (ii) 
the mechanistic target of rapamycin complex 1 (mTORC1) and amino acid sensors, (iii) the salvage 
pathway, which regulates the metabolism of NAD+ and the NAD+-consuming factor SIRT1, (iv) the 
energy sensor adenosine monophosphate-activated protein kinase (AMPK), and (v) the circadian pathway 
in the mouse liver. We formulate the model for a young mouse and an aged mouse, and we apply the 
model to investigate the synergy among regulators of nutrients, energy, metabolism, and circadian 
rhythms. Last but not the least, we conduct simulations to assess the effect of dosing schedule on the 
pharmacodynamics of anti-ageing drugs, of which the key molecular target of these drugs is SIRT1. 
Because SIRT1 is under major influence by the circadian clock(180), the optimal dosing times for these 
medications remain an essential but unanswered question. The model also can be used to aid in the 
interpretation of time dynamic genomic and proteomic data. 
 
37 
4.2 Model description 
 
Figure 15. Schematic representation of the circadian clock, energy and metabolism pathways, and their 
coupling. Some components in the metabolism pathway may be activated by amino acids, such as leucine 
(blue circles) and insulin (green triangles). The model represents three distinct areas in the cell: the 
cytoplasm, lysosome, and the nucleus. 
 
Main model components include the insulin/IGF-1 and mTOR signaling pathway(154), the core 
circadian clock pathway(188), and key metabolism regulators AMPK, NAD+, and SIRT1. The dynamics 
of the signaling pathways are modelled as a system of ODEs. Figure 15 depicts the pathways and protein 
interactions. The reactions and associated parameters are presented in Table S1 in the Supplemental 
Materials. Model parameters are taken from published studies (39, 154, 188). New parameters that 
characterize the coupling between the energy/metabolic pathways and the circadian system are shown in 
Table S2. Additional parameters that are adjusted to fit experimental data(188) are also included in Table 
S2. Parameter fitting was performed using the interior point optimization method in MATLAB.  
Within the insulin/IGF-1 signaling and mTOR pathways, insulin activates the insulin receptor 
(IR), which triggers the IRS and PI3K, resulting in the phosphorylation of PDK1 and mTORC2, 
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respectively. mTORC2 phosphorylates AKT on the S473 and T308 residues, whereas PDK1 activates 
AKT. Active AKT phosphorylates a variety of proteins, including TSC1_TSC2 and PRAS40. 
Phosphorylation of TSC1_TSC2 by AKT inactivates the TSC complex, thereby activating mTORC1 and 
resulting in a number of downstream effects, including the repression of the autophagy pathway and 
elevation of core clock protein BMAL1. A detailed description of the insulin/IGF-1 signaling and mTOR 
pathway model can be found in the previous chapters. A detailed description of the insulin/IGF-1 
signaling and mTOR pathway model can be found in Ref (154). 
The clock model comprises several transcription factors that regulate gene expression: period 
(Per), cryptochromes (Cry), Rev-Erb and ROR-related orphan receptor retinoic acid receptor-related 
orphan receptor (Ror), brain and muscle ARNT-Like 1 (Bmal1), and circadian locomotor output cycles 
kaput (CLOCK). These core clock components exhibit circadian oscillations, driven by a network of 
interlocked transcriptional-translational feedback loops. In the primary negative feedback loop, CLOCK 
and BMAL1 heterodimerize to initiate the transcription of target clock genes, including Per (with 
isoforms Per1, Per2, Per3) and Cry (with isoforms Cry1 and Cry2), by binding the E-box elements in the 
promoter region (46, 204). PERs and CRYs then heterodimerize to inhibit their own transcription by 
acting on CLOCK:BMAL1 protein complex. In the secondary feedback loop, activators of CLOCK and 
BMAL1 dimerize to initiate the transcription of Rev-Erbα and Ror (141, 175). REV-ERBs and RORs are 
shown to repress and activate Bmal1 transcription, respectively (35, 64, 108). In addition, REV-ERB also 
inhibits Cry transcription to ensure robust oscillations (28, 146). Following the approach in Ref. (188), we 
represent the two period homologs (Per1 and Per2) as a single Per gene and ignore Per3, and we represent 
the two cryptochromes (Cry1, Cry2) as a single Cry gene.  
Circadian rhythms play a critical role in the physiological processes involved in energy 
metabolism and energy balance. In turn, mTORC1 regulates the proteostasis of the core clock protein 
BMAL1, affecting its translation, degradation, and subcellular localization (107). Specifically, activation 
of mTORC1 results in elevated levels of BMAL1, but also translocates BMAL1 to the cytoplasm and 
reduces its nuclear accumulation (107, 143). In a negative feedback loop, BMAL1 inhibits the 
phosphorylation of mTORC1, as does another core clock protein PER2 (190).  SIRT1 triggers the 
deacetylation of PGC1-a, the deacetylation of CLOCK-BMAL1 complex, and the degradation of PER2. 
AMPK accelerates the phosphorylation of PGC1-a, as well as the degradation of PER2 and CRY1. 





Modeling the Effect of Ageing on the Circadian Clock and Metabolism: 
Implications on Timing of Medication 
5.1 Introduction 
In the previous chapter we described a computational model that consists of both metabolism and clock 
key players. In this chapter, we conduct model simulations to (1) demonstrate the agreement between 
model predictions and experimental data; (2) investigate how our feeding and fasting cycle can affect 
liver circadian clock, and how these feeding behaviors affect key metabolism regulators such as 
mTORC1; (3) study the effect of ageing on key clock components; (4) analyze the pharmacological 
effects of ageing drugs such as STACs and NAD supplements on clock, and how these effects differ 
between old and aged groups. 
5.2 Model predicts expression time-profiles of core clock genes in the mouse liver 
The intricate coupling of the energy and metabolism pathways and the circadian system is 
represented in the model; see Fig 15. The phosphorylation of mTORC1 elevates BMAL1, whereas 
BMAL1 and PER2 inhibit mTORC1. As such, the circadian rhythms drive oscillations in phosphorylated 
mTORC1 level (Fig. 16B). The model predicts a phase difference between mTORC1 and Bmal1 mRNA 
of ~9 hours. Similar oscillations are seen in other variables in the insulin pathway model. These results 
were obtained for the “young” model with a constant baseline insulin level.  
To assess the validity of the model, we compare the predicted time-profiles of core clock genes 
with mRNA levels measured in mouse livers (78). In that study, the mice were entrained to a 12:12 
light/dark cycle, then put in constant darkness and fed ad libitum. The predicted core clock mRNA time-
profiles for Bmal1 (Fig. 16A), Per2 (Fig. 16C), Cry1 (Fig. 16D), Rev-Erb (Fig. 16E), and Ror (Fig. 16F) 




Figure 16. Predicted oscillations in core clock gene and mTORC1 levels. A, predicted Bmal1 mRNA 
time profile. B, mTORC1 level, driven to oscillate by the clock. C-F, predicted Per2, Cry1, Rev-Erb, and 
Ror time-profiles. Experimental data are shown in closed circles. 
 
5.3 Effect of feeding on mTORC1 and liver clock genes 
The circadian system, metabolism, and feeding are intertwined. To better understand the effect of food on 
liver circadian rhythms, we simulate a fed-like state and a fasted-like state. Nutrition levels (i.e., insulin 
and amino acid) are assumed to stay high at the baseline levels in a fed-like state, to stay low in a fasted-




The time-profiles predicted for mTORC1 and key clock proteins are shown in Fig. 17 (blue and 
red curves). mTORC1 is activated by a high-energy diet through the uptake of glucose and amino acids 
(Fig. 17B). At high nutrition levels, the elevated insulin and growth factor levels promote the 
phosphorylation of Akt, which inhibits TSC1-TSC2 and activates mTORC1. Conversely, in the fast-like 
state, phosphorylated mTORC1 drops to ¼ of its value in the fed-like state, and its circadian oscillations 
essentially vanish. Recall that activation of mTORC1 results in elevated levels of BMAL1. Thus, fasting 
lowers BMAL1 level (Fig. 17C). CLOCK-BMAL and CRY1 are similarly affected, whereas the effect on 
PER2 is the opposite (Figs. 17D-17F). 
 
Figure 17. Effects of feeding schedule on mTORC1 and core clock gene levels. A, insulin levels for a 
fed-like state (constant at 1), a fasted-like state (constant at 0.1), day-time feeding, and night-time feeding. 
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B, mTORC1 levels, driven to oscillate by the clock and feeding schedule, and elevated at high insulin 
levels. C-F, core clock protein time-profiles. 
 
5.4 The liver circadian clock entrains to an altered feeding schedule 
Food is known to be a potent zeitgeber for the liver circadian cycle. To assess the effect of an altered 
feeding schedule on the circadian rhythm, we simulate day-time and night-time feeding by varying the 
insulin and amino acid levels during the day. The simulated insulin levels for the different feeding 
patterns are shown in Fig. 17A, green and orange curves. The simulated amino acid levels follow the 
same trend and vary between 0.5 and 1. The model predicts that variations in nutrition levels yield 
oscillations in mTORC1 (see explanation above). Night-time feeding induces a half-day phase shift in the 
mTORC1 (Fig. 17B) relative to the constant fed-like case, and the coupling between mTORC1 and 
BMAL1 induces a corresponding phase shift in the clock as well (see orange curves in Figs. 17C-17F). 
This result suggests that the liver circadian clock may entrain to an altered feeding schedule via its 
coupling with mTORC1. 
 
5.5 Effect of ageing on the circadian clock 
As we age, our circadian system undergoes significant changes, such that rhythmic activities such as 
sleep/wake patterns change markedly, and in many cases become increasingly fragmented. Ageing is also 
associated with the reduction in the cellular concentration of NAD+ and SIRT1. To study the effect of 
key age-related changes in metabolism on the circadian system, we formulate an aged model by lowering 
the mean NAD+ and SIRT1 levels to 25% and 40%, respectively, of the baseline (young) model (113). 
We acknowledge that ageing is associated with a multitude of other physiological changes. But here we 
focus on the effect of NAD+ and SIRT1, which are known to play an essential role in the mechanism that 




Figure 18. Effect of ageing on metabolism and the circadian clock. Ageing reduces the bioavailability of 
NAD+ (A) and SIRT1 (B), which lowers Bmal1 (C) and Clock-Bmal1 levels (D) but has a negligible 
effect on the abundance of Per2 (E) and Cry1 (F). Ageing shortens the circadian period. 
The resulting time-profiles of core clock genes are shown in Fig. 18. SIRT1 deacetylates the liver 
kinase B1 (LKB1), which stimulates AMPK. Through their actions on PGC1-a, SIRT1 and AMPK raise 
the level of Bmal1. Thus, the lower SIRT1 and AMPK levels in the aged model yield correspondingly 
reduce Bmal1 and Clock-Bmal1 (Figs. 18C and 18D). Taken in isolation, the lower Clock-Bmal1 level 
would decrease the generation rates of Per2 and Cry. However, in a competing effect, the lower SIRT1 
level in the aged model also inhibits the deacetylation of Clock-Bmal1, thereby accelerating the formation 
of Per2 and Cry1. These two competing effects result in negligible effects on the abundance of Per2 and 
Cry1 (Figs. 18E and 18F). What is noteworthy is that the lower SIRT1 level shortens the circadian period 
in the aged model, from the baseline 24 hours to 22 hours, consistent with experimental findings (195). 
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5.6  Effect of dosing schedule on pharmacodynamics 
Resveratrol and other SIRT1-activating compounds (STACs) increase SIRT1 activity and mimic the anti-
ageing effects of calorie restriction in lower organisms and mice (75). Given the modulation of SIRT1 by 
the circadian clock and vice versa, we investigate how the dosing schedule may differentially affect the 
pharmacodynamics of STAC on the young and aged models. The models compute SIRT1 activity as a 
Michaelis-Menten function of [NAD+]. To simulate the effect of STAC, we reduce the Michaelis-Menten 
constant Km (120) and vary SIRT1 generation during the day. We compare the cases where the STAC is 
taken at ZT6, ZT12, and ZT24. The predicted NAD+ time-profiles are shown in Figs. 19D and 19G for 
the young and aged models, respectively. All NAD+ profiles are normalized with respect to the mean 
NAD+ value in the young model. The corresponding predicted SIRT1 time-profiles are in Figs. 19E and 
19H, normalized by the mean SIRT1 value in the young model. Recall that NAD+ and SIRT1 levels are 
attenuated in ageing. As a result, the pharmacodynamics of STAC and its dosing schedule differ 
significantly between the two populations. 
The young and aged models exhibit different responses to the dosing schedule. Given that 
mammalian SIRT1 deacetylates a host of target proteins that are important for apoptosis, the cell cycle, 
circadian rhythms, mitochondrial function, and metabolism, we will assess drug response using two 
measures of SIRT1 levels, its mean and peak, computed over a representative circadian period. The peak 
value is important in threshold-based processes. Relative changes in mean and peak SIRT1 for the young 




Figure 19. Effect of dosing schedule on STAC efficacy. Simulations are conducted for STAC 
administered at ZT6, ZT12, and ZT24 (A), and in the young model (results in the second row) and aged 
model (third row). STAC has a major impact on the dynamics of NAD+ (D and G) and SIRT1 (E and H). 
Dosing schedule has a significant effect on mean SIRT1 in the young model but not the aged model (B), 
whereas the effect on peak SIRT is significant in the young model and even stronger in the old model (C). 
D mean and peak SIRT1 for the young and aged models are computed as percentage changes with respect 
to the respective control group (no drug). 
 
In terms of mean SIRT1, the young and aged models exhibit similar relative increases 
(approximately +10%) when STAC is administered at ZT6, which is the middle of the light cycle and 
coincides approximately with the circadian peaks of the NAD+ and SIRT1 in the control group (no drug). 
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See Fig. 19. Because baseline SIRT1 is much higher in the young model, the same relative increase 
implies a much larger net increase in the young model. When administered at ZT12, the beginning of the 
dark cycle, STAC induces the largest increase in mean SIRT1 in the young model (+13.4%), whereas the 
analogous response of the aged model is essentially insensitive to the dosing schedule (+9.5%, Fig. 19B). 
When administered at the end of the dark cycle (ZT24), STAC induces +12.7% and +9.8% increases in 
mean SIRT1 the young and aged models, respectively. In terms of peak SIRT1, drug timing has a 
significant effect on both the young and aged models (see Fig. 19C). The most marked increase in relative 
peak SIRT1 is obtained when STAC is administered to the aged model at ZT6. Alternative dosing 
schedules and the young model yield significant but weaker response in peak SIRT1.  
Further discussion is warranted for the ZT24 case (dosing at the beginning of the light period). 
Double peaks emerge in the NAD+ and SIRT1 time-profiles (orange curves in Figs. 19D, 19E, 19G, 
19H), with one peak corresponding to the circadian peak, the other to the STAC-induced peak. Also, 
Bmal1 time-profiles indicate a 7-hour shift in the circadian clock, in both the young and aged models 
(Figs. 19F and 19I). Such a shift may be undesirable.  
NAD+ is a central regulator of metabolism, and its decline is linked to DNA damage (20), 
metabolic stress, chronic inflammation (80), and ageing (22, 114). The consumption of nicotinamide 
riboside (NR), a precursor of NAD+ and is similar to B3, has been proposed as a means to elevate NAD+ 
levels and to improve health span (199). To represent the effect of NAD+ supplements, we increase the 
total NAD+ and NAM concentration during specific hours of the day, depending on the dosing schedule 
(Figs. 20A and 20B). We compare the cases where the NAD+ supplements are taken at ZT6, ZT12, and 
ZT24. The predicted NAD+ and SIRT1 time-profiles are shown in Fig. 20 for the young model (panels D 
and E) and the aged model (panels G and H).  
The model predicts that NAD+ supplements exert the strongest effect, as measured by either 
mean or peak SIRT1, if taken during the middle of the light cycle, at ZT6, which coincides with the peak 
of the circadian peak (Figs. 20B and 20C). The model predicts that mean SIRT1 increases by 7.5% in the 
young case and 5.6% in the aged case. If peak SIRT1 is the measure, then a larger increase of 14.2% is 
predicted in the aged model, compared to 36.0% in the young model. Administering NAD+ supplements 
at a different hour may generate significantly smaller effect. Taken at ZT12, mean SIRT1 increases by 
6.6% in the young model and 3.0% in the aged model (Fig. 20B). Unlike the ZT6 case, the ZT12 case 
results in a smaller increase in peak SIRT1 in the aged model (5.7%), compared to 10.8% in the young 
model (Fig. 20C). Taken at ZT24, mean SIRT1 increases by only 3.9% in the baseline model, but 
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essentially has no response (+0.5%) in the aged model (Fig. 20B). Even more remarkably, peak SIRT1 
decreases by 7.9% in the aged model (Fig. 20C). Furthermore, unlike STAC, taking NAD+ supplements 
at ZT24 does not result in a phase shift of the circadian rhythms; see Bmal1 time-profiles in Figs. 20F and 
20I. 
 
Figure 20. Effect of dosing schedule on NAD+ supplement efficacy. Simulations are conducted for 
NAD+ supplement administered at ZT6, ZT12, and ZT24 (A), and in the young model (second row) and 
aged model (third row). NAD+ supplement has a major impact on the dynamics of NAD+ (D and G) and 
SIRT1 (E and H). Dosing schedule has a significant effect on drug efficacy in both the young and old 





6.1 Cell energy balance and metabolism 
6.1.1 Interactions among mTORC, AMPK, and SIRT 
Traditionally, the investigation of human ageing and disease has relied on cell cultures and animal 
models, including non-vertebrates (e.g., yeast, worm, and fly) and vertebrates (e.g., zebrafish, mice, dogs, 
and primates), as well as clinical trials. With the advent of bioinformatics and computational biology, 
computational modeling and analysis techniques can provide accurate simulations of biological processes. 
Chapters 2 and 3 describe a state-of-the-art computational model for investigating signaling pathways in 
growth, ageing, metabolism, and disease in mammals. Major model components include the insulin/IGF-
1 or mTOR signaling pathway (103), the Preiss-Handler and salvage pathways (43), energy sensor 
AMPK, and transcription factors FOXO and PGC-1a. The mTOR signaling pathway couples energy and 
nutrient abundance to the execution of cell growth and division. That function can be attributed to the 
ability of mTORC1 to sense energy, nutrients, and growth factors, by regulating other important kinases, 
such as S6K and AKT. The Preiss-Handler and salvage pathways regulate the metabolism of NAD+ as 
well as NAD+-consuming proteins such as sirtuins. Key findings include: 
• Model simulations indicate that simultaneously inhibiting AKT or PI3K_PDK1, and inhibiting 
mTORC1 effectively suppresses PRAS40 phosphorylation on both Ser183 and Thr246 sites, 
further enhancing the inhibition of mTORC1 by PRAS40 (Fig. 2). This result suggests a 
clinically important role of PRAS40 in controlling tumor growth.  
• We provide the first computational model that capitulates the interplay between sestrin2 and 
leucine, and the effect on mTORC1 activity. With a crucial role in metabolic regulation through 
the activation of AMPK and inhibition of mTORC1, sestrin2 might serve as a therapeutic target 
for cancers, metabolic diseases, and neurodegenerative diseases.  
• Given that sestrin2’s inhibitory effect on mTORC1 activity can be significantly impacted by AAs 
such as leucine (Fig. 6), dietary modifications may enhance the efficacy of therapies that target 
mTORC1 and sestrin2. 
• The model captures the interactions between arginine and leucine during protein deprivation, and 
predicts a signal that reactivates mTORC1 and downregulates autophagy (Fig. 8).  
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• The model capitulates the regulation of autophagy by SIRT1. Simulations indicate that, by 
activating SIRT1, STACs in high dosages may lead to premature autophagy (Fig. 12).  
mTORC1 signaling is switched on by a number of oncogenic signaling pathways and is 
hyperactive in up to 70% of all human tumors (50). Thus, there is much interest in targeting mTORC1 
signaling as a potential therapeutic avenue for anti-cancer therapy. Rapamycin, originally developed as an 
immunosuppressant that targets T-cells, is arguably the best known mTORC1 inhibitor and has been 
shown to extend lifespan in mice.(69) However, despite its specificity, rapamycin in typical dosages does 
not completely inhibit all mTORC1 activities (173), limiting its efficacy as an anti-cancer agent. In fact, 
cancer patients whose tumors exhibit a mutational activation of PI3K/AKT signaling have a low response 
rate for rapamycin and its rapalogs (e.g. breast, colon and prostate cancer, and glioblastoma (13, 62)). 
This inadequate therapeutic response is believed to result from rapamycin and its rapalogs’ incomplete 
inhibition of mTORC1-mediated phosphorylation of 4E-BP1 and a concomitant activation of AKT via 
loss of a negative feedback mechanism (103). 
 Mi et al. suggested that the acquired resistance to rapamycin in cancer cells may be attributable to 
the redundant phosphorylation of PRAS40 by both AKT and mTORC1 signaling (118). Their findings 
indicate that the concurrent inhibition of AKT and mTORC1 yields effective inhibition of PRAS40 
phosphorylation on both Ser183 and Thr246 sites, enhancing PRAS40’s inhibition of mTORC1-mediated 
4E-BP1 phosphorylation and translation, associated with suppression of tumor growth and cell motility 
(118). Similarly, while PI3K inhibitors such as wortmannin are potential anti-cancer agents on their own 
(172), a more nearly complete inhibition of mTORC1 may be achieved when inhibitors of the PI3K/AKT 
pathway are administered in conjunction with rapamycin (Fig. 2). These results suggest a potentially 
important role of PRAS40 in the translational control of tumor progression. Indeed, dual inhibition of 
PI3K and mTORC1 signaling by rapalogs in combination with PI3K or AKT inhibitors has demonstrated 
profound efficacy in preclinical cancer models (21, 49, 106, 138). 
 Chronic administration of rapamycin leads to insulin resistance due to its suppression of 
mTORC2, resulting in glucose intolerance and hepatic insulin resistance (102). The loss of insulin 
sensitivity is due to the reduction of AKT_T308_S473, which plays a pivotal role in the translocation of 
GLUT4 (53, 74). Sebastian and co-workers demonstrated intermittent administration of rapamycin (e.g., 
once every 5 days) mitigates its detrimental effect on glucose homeostasis (5, 6). Our model simulations 
indicate that an optimal rapamycin dosage can be identified which, in chronic and continuous usage, 
attenuates the detrimental effect on insulin sensitivity while preserving rapamycin’s anti-cancer and anti-




6.1.2 Amino acid sensors and mTORC1 regulation 
Sestrin2 is a highly conserved stress-inducible metabolic protein known to provide protection to cells 
against oxidative stress, endoplasmic reticulum (ER) stress, and hypoxia. Sestrin2 also plays a key role in 
metabolic regulation through the activation of AMPK and inhibition of mTORC1, with downstream 
effects including autophagy activation, antiapoptotic effects in normal cells, and proapoptotic effects in 
cancer cells (72). As such, sestrin2 might serve as a potential therapeutic target for cancers (77),(189), 
metabolic diseases, and neurodegenerative diseases (136).  
 The present model provides the first computational platform that capitulates the regulation of 
mTORC1 by sestrin2, and its modulation of leucine. The action of sestrin2 on mTORC1 begins with its 
inhibition of GATOR2. During acute starvation, sestrin2 binds to GATOR2 and impedes the latter’s 
inhibition of GATOR1, resulting in the suppression of mTORC1. Sestrin2 binds with leucine; the 
addition of leucine would reduce free sestrin2, promote the downstream inhibition of GATOR1 and 
ultimately enhance the activation of mTORC1. The interplay between sestrin2 and leucine, and the effect 
on mTORC1 activity is captured in Fig. 6. As noted above, sestrin2 is a potential target for anti-cancer 
and other disease treatments. Given that sestrin2’s inhibitory effect on mTORC1 activity can be 
significantly impacted by AAs such as leucine, dietary modifications may enhance the efficacy of 
therapies that target mTORC1 and sestrin2. 
 GATOR1 negatively regulates mTORC1 and appears to function as a tumor suppressor. In cancer 
cells with loss-of-function mutations in GATOR1, which include some lung, breast, ovarian cancers, and 
glioblastomas (11), mTORC1 is hyperactive and these cancer cells have been shown to be hypersensitive 
to rapamycin. Thus, the associated cancers may be particularly amenable to therapeutic strategies that 
limit mTORC1 activity. For rapamycin-resistant cancers, and for diabetes and neurodegenerative 
diseases, GATOR may be a potential therapeutic target. In fact, as an upstream regulator of mTORC1, 
GATOR1 has been identified as a potential therapeutic target for epilepsy, in which mTORC1 
hyperactivation has been implicated (126). 
 Also contributing to cellular AA sensing for the mTORC1 pathway is the CASTOR family (33). 
CASTOR1/2 binds to GATOR1 and obstructs the binding process between GATOR1 and GATOR2, 
freeing up GATOR1 to inhibit mTORC1. Unlike sestrin2 which is inhibited by leucine, CASTOR1 binds 
to arginine. Thus, the addition of arginine elevates mTORC1 activity by reducing free CASTOR1.  
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 Another arginine sensor is the lysosomal AA transporter SLC38A9. Arginine stimulates 
SLC38A9 and promotes its interaction with the Rag GTPase-Regulator complex, which results in the 
activation of mTORC1. Wyant et al. reported that a mutant of SLC38A9 that does not interact with 
arginine lacks the ability to signal AA sufficiency to mTORC1 (192). Another important role of 
SLC38A9 in AA homeostasis is to transport AAs produced by lysosomal proteolysis, such as leucine, 
from lysosomes to the cytosol, thereby reactivating mTORC1. The critical role of SLC38A9 in this 
process is evinced by the SLC38A9-null HEK293T cells, which exhibit whole-cell AA levels similar to 
wild-type, but significantly higher lysosomal AA concentrations including leucine (192). The efflux of 
lysosomal leucine and the subsequent activation of mTORC1 may regulate autophagy. During starvation, 
mTORC1 is inhibited, which attenuates its inhibitory phosphorylation of ULK1 and promotes autophagy. 
Thus, intracellular nutrients produced by autophagy can stimulate mTORC1 signaling and provide a 
negative feedback signal to downregulate autophagy (more below) (200). The present model is unique in 
that it explicitly and separately represents arginine and leucine, rather than lumping them into a single AA 
category. Consequently, the model captures the exquisite interactions of these AAs, and the resulting 
signal to the mTORC1 pathway and its reactivation during protein deprivation. Indeed, the model is the 
first to recapitulate the reactivation of mTORC1 by proteolysis following autophagy (Fig. 8) (200).  
  
6.1.3 Pharmacological activation of SIRT1 
STACs enhance autophagy via its activation of SIRT1, followed by the activation of AMPK and 
inhibition of the mTORC1. The elevated SIRT1 activity also facilitates the deacetylation of FOXOs, 
which are transcription factors that have major impacts on longevity and cancer. In the absence of growth 
factors or AAs, the reduction in activated AKT leads to the dephosphorylation of FOXOs and drives their 
relocalization from the cytoplasm to the nucleus. The subsequent deacetylation of FOXOs by SIRT1 
mediates stress resistance response. AMPK phosphorylation also increases the transcription activity of 
FOXOs. Emerging evidence suggests that FOXO factors act as a tumor suppressor in a variety of cancers 
(183). 
Additionally, SIRT1 regulates autophagy through the direct deacetylation of autophagy-related 
genes such as ATG. Studies have demonstrated an essential role for SIRT1 in the induction of autophagy 
(68, 104), as well as the protective effects of the SIRT1-induced autophagy in preventing or attenuating 
neurotoxicity (85, 191). However, by activating SIRT1, STACs may lead to the decoupling of the 
autophagic response from the organisms’ nutrient and energy status. Model simulations suggest that a 
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sufficiently potent STAC may yield premature autophagy (Fig. 12), in which newly synthesized cellular 
building blocks are prematurely and unnecessarily catabolized despite an abundance of nutrients.  
 The insulin/IGF-1 signaling pathway of the present model is fitted primarily for C2C12 cells,(40) 
whereas the Preiss-Holder and salvage pathway is formulated primarily using non-specific mammalian 
cell data (16). Because different cells have diverse energetic and metabolic needs, their metabolic 
pathways often exhibit significantly different functions and regulations. For instance, SIRT1 is activated 
by starvation in most cells (131) but in the mouse pancreas, SIRT1 is inactivated by the reduction in the 
NAD+/NADH ratio (18). In C2C12 cells, AMPK does not directly regulate mTORC1 but promotes 
TSC1_TSC2 phosphorylation at ser S1387. Because mTORC1 is inhibited by both TSC1_TSC2 and its 
phosphorylated form TSC1_TSC2_pS1387, in C2C12 cells AMPK appears to have only a limited 
regulatory effect on mTORC1. In contrast, AMPK is known to directly inhibit mTORC1 in HEK293T 
cells (66). Furthermore, sex and age differences have been reported. In the mouse, mTORC1 and 
mTORC2 activity levels are known to vary between males and females (9). In human skeletal muscle, 
mTORC1 is activated under different conditions depending on the age of the individuals (54, 55). 
Similarly, marked changes have been reported in SIRT1 activity and NAD+ levels as individuals age (30, 
196). Last but not the least, molecular mechanisms have been identified that are differentially regulated in 
long- and short-lived species; e.g., perturbed insulin/ IGF-1 signaling in long-lived species due to reduced 
plasma IGF-1 and brain IGF-1 receptor expression (174). Thus, an interesting question is: Multiple 
regulatory mechanisms are known to modulate lifespan in model organisms, such as the insulin/IGF-1 
signaling, the mTOR pathway, and the AMPK pathway. To what extent do these mechanisms account for 
the huge variation of mammalian lifespans in natural species? Taken together, these observations 
highlight the importance of taking into account cell or tissue specificity, together with sex and age, when 
developing therapeutic strategies that target these pathways. Investigating how the key ageing regulatory 
pathways interact during normal ageing is a worthwhile future extension. 
 In sum, we have developed a state-of-the-art computational model for investigating the 
interactions among signaling pathways and environmental stimuli in growth, ageing, metabolism, and 
diseases. The model can be used as an essential component to simulate (1) gene manipulation, (2) 
therapies for cancer, metabolic diseases, and neurodegenerative diseases, (3) calorie restrictions, and (4) 




6.2 Circadian rhythms, metabolism, and ageing 
6.2.1 Metabolism and the circadian rhythms 
Early work in mammalian rhythms identified the hypothalamic SCN as the master circadian pacemaker 
that drives behavioral rhythms (185). Soon after, it was realized that circadian genes expression is by no 
means limited to the SCN but can be found in cells throughout the body (46). Indeed, the cell-autonomous 
clock is ubiquitous (10, 127, 198), with most peripheral organs and tissues simultaneously exhibiting 
autonomous circadian oscillations and receiving signals from the SCN. In different cell types, the 
circadian oscillators respond differently to entraining signals. SCN gene expression responds rapidly to 
light, a tight coupling that is mediated by the neural connections from the SCN and the retina to the SCN. 
As a result, SCN gene expression entrains to a shifted light/dark schedule within a day (194). 
Interestingly, while other nonphotic stimuli, like a shifted feeding schedule, can dominate light in 
entraining behavioral and peripheral rhythms, the SCN is hard-wired to the light/dark rhythm. 
Unlike the SCN, light exerts only a weak entraining effect on the liver. Experiments in the rat 
demonstrate the even after 16 days of an altered light/dark regimen, the liver clock does not completely 
adapt to the new schedule (194). In contrast, feeding is a potent zeitgeber for the liver circadian cycle. A 
restricted feeding protocol, in which mice are given food access for a limited period during the light 
(inactive) phase, almost immediately resets the phase of circadian gene expression in the liver (42, 169). 
Indeed, the liver circadian clock is one of the fastest tissue clocks to entrain to an altered feeding 
schedule, indicating that its coupling to food intake is significantly stronger than to peripheral or central 
oscillators. To understand the mechanism that underlies this entrainment, we conduct a simulation of day-
time and night-time feeding. Simulation results indicate that the coupling of the liver circadian clock to 
mTORC1 plays a key role in its entrainment to an altered feeding schedule (Fig. 17). 
The interactions between metabolism and circadian rhythms in humans can be gleaned from 
clinical observations in shift workers. Shift work involves alternations in feeding schedule and other 
zeitgebers. A higher incidence of diabetes, obesity, and cardiovascular events has been reported among 
shift workers (12, 168), although the underlying mechanisms have yet to be elucidated. Participants 
subjected to forced circadian misalignment (a simulation of shift work) have been found to exhibit insulin 
resistance and elevated blood pressure (161). Our simulation of nighttime feeding (one aspect of shift 
work) predicts lowered phosphorylated Akt levels, compared to daytime feedback. Phosphorylated Akt is 
essential to the translocation of GLUT4; thus, our result suggests that nighttime feedback may lead to 
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impaired glucose tolerance. It is noteworthy that patients with diabetes exhibit a dampened amplitude of 
circadian rhythms of insulin secretion (17) and glucose tolerance. Given this bidirectional nature of the 
relationship between circadian disruption and metabolic pathologies, circadian disruption may lead to a 
vicious cycle and contribute to the progression and worsening of metabolic diseases. 
 
6.2.2 Ageing and the circadian rhythms 
In ageing, a gradual decline is seen in a number of physiological functions, including the robustness of the 
circadian clock. Documented age-related changes in circadian rhythms include shortening of the circadian 
period (124, 139, 184, 186), alteration in the phase angle of entrainment to the light/dark cycle (124, 160, 
202), fragmentation of the activity rhythm (160), decreased precision in the onset of daily activity (160, 
202), and alterations in the response to the phase-shifting effects of light (153, 203) and nonphotic stimuli 
(176). These age-related changes in the circadian system may disrupt the proper phase 
relationships among numerous physiological and behavioral 24-h rhythms, as well as between these 
rhythms and daily environmental cycles. The disruption of those relations may negatively impact the 
organism’s health and its adaptation to the environment (24).  
The interactions between ageing and the circadian clock are complex and likely involve a 
bidirectional relationship (97, 100, 129). Possible mechanisms that contribute to the ageing of the 
circadian clock include changes in the SCN, including its structure (171, 206), neuronal coupling (115, 
130, 159), and clock gene expression (115, 130, 159). The model presented in Chapter 4 focuses on the 
role of SIRT1 and NAD+. In vitro, SIRT1 regulates the acetylation of Bmal1 and Per2 in the mouse liver 
(7, 128) and human hepatocytes (181). SIRT1 expression in the mouse brain and liver decreases with age, 
and Sirt1 knockouts display a premature ageing phenotype, including disrupted activity rhythms 
comparable to those in aged (19–22 months) wild-type mice (32), as well as shortened lifespan and 
increased levels of proinflammatory markers in blood (181). The aged model in Chapter 4 predicts 
attenuated Bmal1, consistent with observations in a knockout of Sirt1 in the brain (32), and a shortened 
circadian period (Fig. 18). Taken together, model simulations and experimental findings concur on a role 
for an age-dependent decrease in SIRT1 activity in mediating changes in the molecular circadian 
clockwork (32, 195). Taken together, model simulations and experimental findings concur on a role for an 
age-dependent decrease in SIRT1 in mediating changes in the molecular circadian clockwork. 
 
55 
Circadian rhythm disturbances in the elderly are associated with a wide range of health 
conditions, including hypertension and cardiac insufficiency (1, 84, 105), impaired immune functions and 
increased susceptibility to disease (83), depression and poor cognitive and psychological functioning 
(123). Common treatments for circadian rhythm disorders in ageing include the use of melatonin(57, 67) 
and light therapy (121). Given the likely involvement of SIRT1 in the dysfunction of the circadian clock 
in ageing, therapies that elevate SIRT1 activity may restore the circadian rhythms and reverse other age-
related effects. In recent studies, supplementation of NAD+ intermediates such as nicotinamide 
mononucleotide (NMN) and NR was reported to dramatically reverse the effects of ageing at the cellular 
and organismal levels (58). Importantly, NAD+ intermediate supplementation appears to restore 
NAD+ levels in both nuclear and mitochondrial compartments of cells, and the benefits of 
NAD+ intermediate supplementation appear to be due to the reactivation of sirtuins. Given the role of the 
circadian clock in optimizing and maintaining health, some of the benefits of NAD+ intermediate 
supplementation may be attributed to the restoration of the circadian rhythms. 
 
6.2.3 Dosing schedule and the circadian rhythms 
In recent years, interest in resveratrol and NAD+ supplements has increased enormously after reports 
emerged on their benefits on metabolism and increased lifespan of various organisms(70, 75). Key 
molecular targets common to these drugs are SIRT1 and NAD+, both of which exhibit significant 
circadian variations (180). Thus, a salient question is: To what extent do dosing times impact the anti-
ageing effects of resveratrol and NAD+ supplements? Indeed, the circadian rhythms have been known to 
modulate drug pharmacokinetics and pharmacodynamics (41). Experimental data involving targeted 
anticancer agents have indicated that both circadian timing and drug dosage are critical factors in 
determining systemic exposure and thus pharmacological effects. For example, Everolimus, an 
immunosuppressant that inhibits mTOR, exerts a higher antitumor efficacy if taken at ZT12 compared to 
ZT0 (134). A link between dosing schedule and drug efficacy was also revealed for a number of other 
anticancer drugs (96, 106, 201), analgesic (44, 86), antidiabetic drugs (122), and antibiotics (167).  
The exact effect of dosing time on pharmacodynamics and pharmacokinetics depends on the drug 
and likely on patient characteristics. The present model focuses on one patient characteristic, age. We 
seek to answer the important clinical question: Given the age of a patient, what is the best time to 
administer STACs or NAD+ supplements, to maximize the drugs’ potential anti-ageing effects? The 
answer depends, first of all, on the measure of drug efficacy. If the goal is to elevate peak SIRT1 (to 
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maximize physiological processes that activate above a SIRT1 threshold), then the best time to administer 
either STACs or NAD+ supplements is to coincide with the circadian peaks of NAD+ and SIRT1 in the 
control group (no drug), i.e., in the middle of the light periods (ZT6). If the goal is to maximize mean 
SIRT1, then the answer depends on the drug (STACs or NAD+ supplements) and on patient’s age. For 
STACs, administering the drug in the young model at the beginning or end of the light periods (ZT12 or 
ZT24) yields a significant, albeit not drastic, improvement in terms of mean SIRT1, over administering it 
in the middle of the light periods (ZT6). The aged model is largely insensitive to dosing timing. For 
NAD+ supplements, administering the drug in the middle of the light periods (ZT6) yields the largest 
increase in mean SIRT1 in both models. These results are summarized in Figs. 19 and 20, panels B and C. 
A noteworthy finding of this work is that caution should be taken when STACs or NAD+ 
supplements are to be taken early in the morning (ZT24). For STACs, not only does this timing yield the 
smallest increase in peak SIRT1, it may also have an undesirable side-effect of shifting the circadian 
clock (Figs. 19F and 19I). The model predicts a 7-hour shift, although in practice other zeitgebers and 
inputs will likely render the circadian clock more robust. For NAD+ supplements, this timing generates 
the smallest increases in both mean and peak SIRT1, and in the aged population, it may even lower the 
SIRT1 peak. 
 
6.2.4 Comparison with previous models and future extension 
In a recent study (63), Guerrero-Morín and Santillán studied the regulation of the circadian clock by 
coupling the minimal genetic oscillator model by Goodwin(59) with a simple mTORC1 activation model. 
That Goodwin model represents the feedback loop involving BMAL1, PER, and CRY, and can reproduce 
features of circadian oscillators such as light entrainment. However, it neglects the feedback loop 
involving BMAL1, REV-ERB, and ROR. That model (63) only considers the unidirectional control of 
BMAL1 by mTROC1, but not the circadian regulation of metabolism, or the influence of other metabolic 
sensors (e.g., AMPK) on the circadian rhythms. 
The goal of this work is to better understand the bidirectional interactions among metabolism and 
the circadian clock, and how those interactions changes in ageing and pharmacological manipulation. To 
achieve that goal, we have developed a more comprehensive mathematical model of circadian rhythms 
and metabolism. We adopt the mammalian liver circadian clock model by Woller et al. (188). In addition 
to the dynamics of the core clock regulatory network, that model also incorporates metabolic sensors 
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SIRT1 and AMPK, and represents additional mechanisms through which metabolism drives the clock. 
Specifically, the model (188) simulates the action of SIRT1 in modulating the transcriptional activity of 
CLOCK:BMAL1 and destabilizing PER2. SIRT1 also activates PGC1a, which co-activates ROR and 
increases Bmal1 expression. But before PGC1a can be deacetylated by SIRT1, phosphorylation by 
AMPK is required. Additionally, activated AMPK destabilizes PER and CRY.  
While the model by Woller et al. can predict how the activation of AMPK alters the circadian 
clock, (i) the AMPK level is assumed known a priori, and (ii) their model does not consider the role of 
mTORC1, which plays a central role in regulating fundamental cell processes, from protein synthesis to 
autophagy, and the signaling of which when dysregulated is implicated in the progression of cancer and 
diabetes, as well as the ageing process. Thus, we couple the circadian clock model (188) to our published 
model of insulin pathway (154), which includes the insulin/IGF-1 pathway, mTORC1, and AMPK, and 
predicts how mTORC1, AMPK, and SIRT1 respond to variations in energy and nutrient abundance. The 
insulin pathway and mTORC1 model (154) and the circadian clock model (188) are coupled by 
representing the increase of BMAL1 protein expression by mTORC1 (107, 143), and the inhibition of 
mTORC1 phosphorylation by BMAL1 and PER2 (190).  
The present model provides a state-of-the-art computational platform for investigating the 
interplay among ageing, metabolism, and circadian rhythms. Model simulations have identified altered 
mTORC1 signaling as a mechanism leading to clock disruption and its associated metabolic effects, and 
suggested a pharmacological approach to resetting the clock in obesity and metabolic diseases. Further, 
mTORC1 signaling is switched on by a number of oncogenic signaling pathways and may be hyperactive 
in up to 70% of all human tumors (50). Thus, there is much interest in targeting mTORC1 signaling as a 
potential therapeutic avenue for anti-cancer therapy. The potential effect of these treatments on the 
circadian clock may be studied using the present model.  
A limitation of the present model is that it considers only the influence of variations in mTORC1, 
AMPK, and SIRT1, and neglects the influence of systemic signals from the SCN. This simplification is 
justified for the liver circadian clock, the entrainment phase of which is determined primarily by the 
feeding schedule. If the present model is to be adapted to other peripheral circadian clocks, the SCN 
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Figure A1. Schematic diagram depicting connections among model components that form the signaling 
pathways. AA represents amino acids; “A” in purple circles denote the acetylated form of the complex; 
“P” in yellow circles denote the phosphorylated form. 
 
Below is a complete list of equations used in the metabolic signaling pathway model described in Chapter 

























 +(𝑝𝑎𝑟_𝐼𝑅_𝑏𝑒𝑡𝑎_𝑟𝑒𝑎𝑑𝑦 ∗ [𝐼𝑅𝛽_𝑟𝑒𝑓𝑟𝑎𝑐𝑡𝑜𝑟𝑦]) 
−([𝐼𝑅𝛽] ∗ 𝑝𝑎𝑟_𝐼𝑅_𝑏𝑒𝑡𝑎_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐼𝑛𝑠𝑢𝑙𝑖𝑛 ∗ [𝐼𝑛𝑠𝑢𝑙𝑖𝑛]) 
 
+([𝐼𝑅𝛽] ∗ 𝑝𝑎𝑟_𝐼𝑅_𝑏𝑒𝑡𝑎_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐼𝑛𝑠𝑢𝑙𝑖𝑛 ∗ [𝐼𝑛𝑠𝑢𝑙𝑖𝑛])	
−(𝑝𝑎𝑟_𝐼𝑅_𝑏𝑒𝑡𝑎_𝑝𝑌1146_𝑑𝑒𝑝ℎ𝑜𝑠 ∗ [𝐼𝑅𝛽_𝑝𝑌1146]) 
 
+(𝑝𝑎𝑟_𝐼𝑅_𝑏𝑒𝑡𝑎_𝑝𝑌1146_𝑑𝑒𝑝ℎ𝑜𝑠 ∗ [𝐼𝑅𝛽_𝑝𝑌1146])	
−(𝑝𝑎𝑟_𝐼𝑅_𝑏𝑒𝑡𝑎_𝑟𝑒𝑎𝑑𝑦 ∗ [𝐼𝑅𝛽_𝑟𝑒𝑓𝑟𝑎𝑐𝑡𝑜𝑟𝑦]) 
 
−([𝑇𝑆𝐶1_𝑇𝑆𝐶2] + [𝑇𝑆𝐶1_𝑇𝑆𝐶2_𝑝𝑆1387]) ∗ [𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448] ∗ 𝑝𝑎𝑟_𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448_𝑑𝑒𝑝ℎ𝑜𝑠_𝑏𝑦_𝑇𝑆𝐶1_𝑇𝑆𝐶2)	
−(𝑏_𝑝𝑟𝑎𝑠_𝑚𝑡𝑜𝑟𝑐1 ∗ 0.00068 ∗ [𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448] ∗ 10^(0.25 ∗ [𝑃𝑅𝐴𝑆40]))	
−([𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448] ∗ [𝐴𝑐𝑡_𝑈𝐿𝐾1] ∗ 0.00016)	
+	[𝐴𝑚𝑖𝑛𝑜_𝐴𝑐𝑖𝑑] ∗ [𝑚𝑇𝑂𝑅𝐶1] ∗ 𝑝𝑎𝑟_𝑚𝑇𝑂𝑅𝐶1_𝑆2448_𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛_𝑏𝑦_𝐴𝑚𝑖𝑛𝑜_𝐴𝑐𝑖𝑑𝑠	
∗ (	
𝑚𝑇𝑂𝑅𝐶1$%&' ∗ ([𝑙𝑒𝑢𝑐𝑖𝑛𝑒&] + [𝑙𝑒𝑢𝑐𝑖𝑛𝑒()*(])
[𝑙𝑒𝑢𝑐𝑖𝑛𝑒&] + [𝑙𝑒𝑢𝑐𝑖𝑛𝑒()*(] + [𝑠𝑒𝑠𝑡𝑟𝑖𝑛2]
	)	
 
+([𝑇𝑆𝐶1_𝑇𝑆𝐶2] + [𝑇𝑆𝐶1_𝑇𝑆𝐶2_𝑝𝑆1387]) ∗ [𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448] ∗ 𝑝𝑎𝑟_𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448_𝑑𝑒𝑝ℎ𝑜𝑠_𝑏𝑦_𝑇𝑆𝐶1_𝑇𝑆𝐶2)	
+(𝑏_𝑝𝑟𝑎𝑠_𝑚𝑡𝑜𝑟𝑐1 ∗ 0.00068 ∗ [𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448] ∗ 10^(0.25 ∗ [𝑃𝑅𝐴𝑆40]))	
+([𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448] ∗ [𝐴𝑐𝑡_𝑈𝐿𝐾1] ∗ 0.00016)	
−	[𝐴𝑚𝑖𝑛𝑜_𝐴𝑐𝑖𝑑] ∗ [𝑚𝑇𝑂𝑅𝐶1] ∗ 𝑝𝑎𝑟_𝑚𝑇𝑂𝑅𝐶1_𝑆2448_𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛_𝑏𝑦_𝐴𝑚𝑖𝑛𝑜_𝐴𝑐𝑖𝑑𝑠	
∗ (	
𝑚𝑇𝑂𝑅𝐶1$%&' ∗ ([𝑙𝑒𝑢𝑐𝑖𝑛𝑒&] + [𝑙𝑒𝑢𝑐𝑖𝑛𝑒()*(])




































−([𝐴𝑚𝑖𝑛𝑜_𝐴𝑐𝑖𝑑] ∗ 	 [𝑚𝑇𝑂𝑅𝐶2] ∗ 𝑝𝑎𝑟_𝑚𝑇𝑂𝑅𝐶2_𝑆2481_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐴𝑚𝑖𝑛𝑜_𝐴𝑐𝑖𝑑𝑠)	
−([𝑃𝐼3𝐾_𝑝] ∗ [𝑚𝑇𝑂𝑅𝐶2] ∗ 𝑝𝑎𝑟_𝑚𝑇𝑂𝑅𝐶2_𝑆2481_𝑝ℎ𝑜𝑠_𝑏𝑦_𝑃𝐼3𝐾_𝑣𝑎𝑟𝑖𝑎𝑛𝑡_𝑝)	
+(𝑝𝑎𝑟_𝑚𝑇𝑂𝑅𝐶2_𝑝𝑆2481_𝑑𝑒𝑝ℎ𝑜𝑠 ∗ [𝑚𝑇𝑂𝑅𝐶2_𝑝𝑆2481])	
 
+([𝐴𝑚𝑖𝑛𝑜_𝐴𝑐𝑖𝑑] ∗ 	 [𝑚𝑇𝑂𝑅𝐶2] ∗ 𝑝𝑎𝑟_𝑚𝑇𝑂𝑅𝐶2_𝑆2481_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐴𝑚𝑖𝑛𝑜_𝐴𝑐𝑖𝑑𝑠)	
+([𝑃𝐼3𝐾_𝑝] ∗ [𝑚𝑇𝑂𝑅𝐶2] ∗ 𝑝𝑎𝑟_𝑚𝑇𝑂𝑅𝐶2_𝑆2481_𝑝ℎ𝑜𝑠_𝑏𝑦_𝑃𝐼3𝐾_𝑣𝑎𝑟𝑖𝑎𝑛𝑡_𝑝)	
−(𝑝𝑎𝑟_𝑚𝑇𝑂𝑅𝐶2_𝑝𝑆2481_𝑑𝑒𝑝ℎ𝑜𝑠 ∗ [𝑚𝑇𝑂𝑅𝐶2_𝑝𝑆2481])	
 
−([𝐴𝑚𝑖𝑛𝑜_𝑎𝑐𝑖𝑑] ∗ [𝐼𝑅𝑆] ∗ 𝑝𝑎𝑟_𝐼𝑅𝑆_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐴𝑚𝑖𝑛𝑜_𝐴𝑐𝑖𝑑𝑠)		
−([𝐼𝑅𝑆] ∗ 	𝑝𝑎𝑟_𝐼𝑅𝑆_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐼𝑅_𝑏𝑒𝑡𝑎_𝑝𝑌1146 ∗ [𝐼𝑅𝛽 − 𝑝𝑌1146])		




+([𝐴𝑚𝑖𝑛𝑜_𝐴𝑐𝑖𝑑] ∗ 	 [𝐼𝑅𝑆] ∗ 	𝑝𝑎𝑟_𝐼𝑅𝑆_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐴𝑚𝑖𝑛𝑜_𝐴𝑐𝑖𝑑𝑠)	
+([𝐼𝑅𝑆] ∗ 	𝑝𝑎𝑟_𝐼𝑅𝑆_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐼𝑅_𝑏𝑒𝑡𝑎_𝑝𝑌1146 ∗	[𝐼𝑅𝛽 − 𝑝𝑌1146])	
−([𝐼𝑅𝑆_𝑝] ∗ 	𝑝𝑎𝑟_𝐼𝑅𝑆_𝑝_𝑝ℎ𝑜𝑠_𝑏𝑦_𝑝70_𝑆6𝐾_𝑝𝑇229_𝑝𝑇389 ∗	[𝑝70𝑆6𝐾_𝑝𝑇229_𝑝𝑇389])	
 
+([𝐼𝑅𝑆_𝑝] ∗ 𝑝𝑎𝑟_𝐼𝑅𝑆_𝑝_𝑝ℎ𝑜𝑠_𝑏𝑦_𝑝70_𝑆6𝐾_𝑝𝑇229_𝑝𝑇389 ∗ [𝑝70𝑆6𝐾_𝑝𝑇229_𝑝𝑇389])	
+([𝐼𝑅𝑆] ∗ 	𝑝𝑎𝑟_𝐼𝑅𝑆_𝑝ℎ𝑜𝑠_𝑏𝑦_𝑝70_𝑆6𝐾_𝑝𝑇229_𝑝𝑇389 ∗	[𝑝70𝑆6𝐾_𝑝𝑇229_𝑝𝑇389])	
−(𝑝𝑎𝑟_𝐼𝑅𝑆_𝑝𝑆636_𝑡𝑢𝑟𝑛𝑜𝑣𝑒𝑟 ∗ [𝐼𝑅_𝑝𝑆636])	
 
−([𝐴𝑀𝑃𝐾_𝑝𝑇172] ∗ 	 [𝑇𝑆𝐶1_𝑇𝑆𝐶2] ∗ 𝑝𝑎𝑟_𝑇𝑆𝐶1_𝑇𝑆𝐶2_𝑆1387_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐴𝑀𝑃𝐾_𝑝𝑇172) 
−(([𝐴𝐾𝑇_𝑝𝑇308] + [𝐴𝐾𝑇_𝑝𝑇3089_𝑝𝑆473]) ∗ [𝑇𝑆𝐶1_𝑇𝑆𝐶2] ∗ 𝑝𝑎𝑟_𝑇𝑆𝐶1_𝑇𝑆𝐶2_𝑇1462_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐴𝑘𝑡_𝑝𝑇308)	
+(𝑝𝑎𝑟_𝑇𝑆𝐶1_𝑇𝑆𝐶2_𝑝𝑆1387_𝑑𝑒𝑝ℎ𝑜𝑠 ∗ [𝑇𝑆𝐶1_𝑇𝑆𝐶2_𝑝𝑆1387])	


































+(([𝐴𝑘𝑡 − 𝑝𝑇308] 	+ [𝐴𝑘𝑡_𝑝𝑇308_𝑝𝑆473]) ∗ [𝑇𝑆𝐶1_𝑇𝑆𝐶2] ∗ 	𝑝𝑎𝑟_𝑇𝑆𝐶1_𝑇𝑆𝐶2_𝑇1462_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐴𝑘𝑡_𝑝𝑇308)	
−(𝑝𝑎𝑟_𝑇𝑆𝐶1_𝑇𝑆𝐶2_𝑝𝑇1462_𝑑𝑒𝑝ℎ𝑜𝑠 ∗ [𝑇𝑆𝐶1_𝑇𝑆𝐶2_𝑝𝑇1462])	
 
+([𝐴𝑀𝑃𝐾 − 𝑝𝑇172] ∗	 [𝑇𝑆𝐶1_𝑇𝑆𝐶2] ∗ 𝑝𝑎𝑟_𝑇𝑆𝐶1_𝑇𝑆𝐶2_𝑆1387_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐴𝑀𝑃𝐾_𝑝𝑇172)	
−(𝑝𝑎𝑟_𝑇𝑆𝐶1_𝑇𝑆𝐶2_𝑝𝑆1387_𝑑𝑒𝑝ℎ𝑜𝑠 ∗ [𝑇𝑆𝐶1_𝑇𝑆𝐶2_𝑝𝑆1387])	
 
−([𝑃𝑅𝐴𝑆40] ∗ 𝑝𝑎𝑟_𝑃𝑅𝐴𝑆40_𝑆183_𝑝ℎ𝑜𝑠_𝑏𝑦_𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448_𝑓𝑖𝑟𝑠𝑡 ∗ [𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448])	




+([𝑃𝑅𝐴𝑆40] ∗ 𝑝𝑎𝑟_𝑃𝑅𝐴𝑆40_𝑆183_𝑝ℎ𝑜𝑠_𝑏𝑦_𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448_𝑓𝑖𝑟𝑠𝑡	 ∗ [𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448])	




−(𝑝𝑎𝑟_𝑃𝑅𝐴𝑆40_𝑆183_𝑝ℎ𝑜𝑠_𝑏𝑦_𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448_𝑠𝑒𝑐𝑜𝑛𝑑 ∗ [𝑃𝑅𝐴𝑆40_𝑝𝑇246] ∗ 	 [𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448])	
−(𝑝𝑎𝑟_𝑃𝑅𝐴𝑆40_𝑝𝑇246_𝑑𝑒𝑝ℎ𝑜𝑠_𝑓𝑖𝑟𝑠𝑡 ∗ [𝑃𝑅𝐴𝑆40_𝑝𝑇246])	
+([𝐴𝑘𝑡_𝑝𝑇308] ∗ 	 [𝐴𝑘𝑡_𝑝𝑇308_𝑝𝑆473] ∗ 	 [𝑃𝑅𝐴𝑆40] ∗ 𝑝𝑎𝑟_𝑃𝑅𝐴𝑆40_𝑇246_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐴𝑘𝑡_𝑝𝑇308_𝑓𝑖𝑟𝑠𝑡)	
+(𝑝𝑎𝑟_𝑃𝑅𝐴𝑆40_𝑝𝑆183_𝑑𝑒𝑝ℎ𝑜𝑠_𝑠𝑒𝑐𝑜𝑛𝑑 ∗ [𝑃𝑅𝐴𝑆40_𝑝𝑇246_𝑝𝑆183])	
 
+(([𝐴𝑘𝑡_𝑝𝑇308] +	[𝐴𝑘𝑡_𝑝𝑇308_𝑝𝑆473]) ∗ [𝑃𝑅𝐴𝑆40_𝑝𝑆183] ∗ 𝑝𝑎𝑟_𝑃𝑅𝐴𝑆40_𝑇246_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐴𝑘𝑡_𝑝𝑇308_𝑠𝑒𝑐𝑜𝑛𝑑)	





































−([𝐴𝐾𝑇] ∗ 	𝑝𝑎𝑟_𝐴𝑘𝑡_𝑇308_𝑝ℎ𝑜𝑠_𝑏𝑦_𝑃𝐼3𝐾_𝑝_𝑃𝐷𝐾1_𝑓𝑖𝑟𝑠𝑡 ∗ 	 [𝑃𝐷𝐾1_𝑝])	




+(𝑝𝑎𝑟_𝐴𝑘𝑡_𝑇308_𝑝ℎ𝑜𝑠_𝑏𝑦_𝑃𝐼3𝐾_𝑝_𝑃𝐷𝐾1_𝑠𝑒𝑐𝑜𝑛𝑑 ∗ [𝐴𝑘𝑡_𝑝𝑆473] ∗ 	 [𝑃𝐷𝐾1_𝑝])	




+([𝐴𝐾𝑇] ∗ 	𝑝𝑎𝑟_𝐴𝑘𝑡_𝑇308_𝑝ℎ𝑜𝑠_𝑏𝑦_𝑃𝐼3𝐾_𝑝_𝑃𝐷𝐾1_𝑓𝑖𝑟𝑠𝑡 ∗ [𝑃𝐷𝐾1_𝑝])	






+(𝑝𝑎𝑟_𝑃𝐼3𝐾_𝑃𝐷𝐾1_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐼𝑅𝑆_𝑝 ∗ [𝐴𝐾𝑇] ∗ [𝑃𝐼3𝐾_𝑝_𝑃𝐷𝐾1])	
−(𝑝𝑎𝑟_𝐴𝑘𝑡_𝑆473_𝑝ℎ𝑜𝑠_𝑏𝑦_𝑚𝑇𝑂𝑅𝐶2_𝑝𝑆2481_𝑓𝑖𝑟𝑠𝑡) ∗ [𝐴𝐾𝑇_𝑝𝑇308] ∗ [𝑚𝑇𝑂𝑅𝐶2_𝑝𝑆2481])	
 
−([𝑃𝐷𝐾1_𝑝] ∗ 	 [𝑝70𝑆6𝐾] ∗ 𝑝𝑎𝑟_𝑝70_𝑆6𝐾_𝑇229_𝑝ℎ𝑜𝑠_𝑏𝑦_𝑃𝐼3𝐾_𝑝_𝑃𝐷𝐾1_𝑓𝑖𝑟𝑠𝑡)	








































+([𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448] ∗ 	 [𝑝70𝑆6𝐾] ∗ 	𝑝𝑎𝑟_𝑝70_𝑆6𝐾_𝑇389_𝑝ℎ𝑜𝑠_𝑏𝑦_𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448_𝑓𝑖𝑟𝑠𝑡)	




+(𝑃𝐷𝐾1+ ∗ 𝑝𝑎𝑟_𝑝70_𝑆6𝐾_𝑇229_𝑝ℎ𝑜𝑠_𝑏𝑦_𝑃𝐼3𝐾_𝑝_𝑃𝐷𝐾1_𝑠𝑒𝑐𝑜𝑛𝑑 ∗	[𝑝70𝑆6𝐾_𝑝𝑇389])	





−([𝐼𝑅𝛽_𝑝𝑌1146] ∗ [𝑃𝐼3𝐾] ∗ 𝑝𝑎𝑟_𝑃𝐼3𝐾_𝑣𝑎𝑟𝑖𝑎𝑛𝑡_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐼𝑅_𝑏𝑒𝑡𝑎_𝑝𝑌1146)	
 
−(𝑝𝑎𝑟_𝑃𝐼3𝐾_𝑣𝑎𝑟𝑖𝑎𝑛𝑡_𝑝_𝑑𝑒𝑝ℎ𝑜𝑠 ∗ [𝑃𝐼3𝐾_𝑝])	
+([𝐼𝑅𝛽_𝑝𝑌1146] ∗ [𝑃𝐼3𝐾] ∗ 𝑝𝑎𝑟_𝑃𝐼3𝐾_𝑣𝑎𝑟𝑖𝑎𝑛𝑡_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐼𝑅_𝑏𝑒𝑡𝑎_𝑝𝑌1146)	
 
+(𝑝𝑎𝑟_𝑃𝐼3𝐾_𝑝_𝑃𝐷𝐾1_𝑑𝑒𝑝ℎ𝑜𝑠 ∗ [𝑃𝐷𝐾1_𝑝])	
−([𝐼𝑅𝑆_𝑝] ∗ 	 [𝑃𝐷𝐾1] ∗ 	𝑝𝑎𝑟_𝑃𝐼3𝐾_𝑃𝐷𝐾1_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐼𝑅𝑆_𝑝)	
 
−(𝑝𝑎𝑟_𝑃𝐼3𝐾_𝑝_𝑃𝐷𝐾1_𝑑𝑒𝑝ℎ𝑜𝑠 ∗ [𝑃𝐷𝐾1_𝑝])	




































−(100 ∗ [𝐴𝑀𝑃𝐾] ∗ 𝑝𝑎𝑟_𝐴𝑀𝑃𝐾_𝑇172_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐴𝑚𝑖𝑛𝑜𝐴𝑐𝑖𝑑𝑠 ∗ [𝑙𝑒𝑢𝑐𝑖𝑛𝑒_𝑐𝑜𝑛𝑐] ∗ [𝑠𝑒𝑠𝑡𝑟𝑖𝑛𝑒_𝑐𝑜𝑛𝑐])	
−([𝐴𝑀𝑃𝐾] ∗ 	𝑝𝑎𝑟_𝐴𝑀𝑃𝐾_𝑇172_𝑝ℎ𝑜𝑠 ∗	 [𝐼𝑅𝑆_𝑝])	
+(𝑝𝑎𝑟_𝐴𝑀𝑃𝐾_𝑝𝑇172_𝑑𝑒𝑝ℎ𝑜𝑠 ∗ [𝐴𝑀𝑃𝐾_𝑝𝑇172])	
−(𝑘𝑠𝑖𝑟𝑡 ∗ [𝑆𝐼𝑅𝑇] ∗ [𝐴𝑀𝑃𝐾])	
+([𝐴𝑐𝑡_𝑈𝐿𝐾1] ∗ [𝐴𝑀𝑃𝐾_𝑝𝑇172] ∗ 𝑘𝑈𝐾𝐴𝑃)	
 
+(100 ∗ [𝐴𝑀𝑃𝐾] ∗ 𝑝𝑎𝑟_𝐴𝑀𝑃𝐾_𝑇172_𝑝ℎ𝑜𝑠_𝑏𝑦_𝐴𝑚𝑖𝑛𝑜𝐴𝑐𝑖𝑑𝑠 ∗ [𝑙𝑒𝑢𝑐𝑖𝑛𝑒_𝑐𝑜𝑛𝑐] ∗ [𝑠𝑒𝑠𝑡𝑟𝑖𝑛𝑒_𝑐𝑜𝑛𝑐])	
+([𝐴𝑀𝑃𝐾] ∗ 	𝑝𝑎𝑟_𝐴𝑀𝑃𝐾_𝑇172_𝑝ℎ𝑜𝑠 ∗	 [𝐼𝑅𝑆_𝑝])	
−(𝑝𝑎𝑟_𝐴𝑀𝑃𝐾_𝑝𝑇172_𝑑𝑒𝑝ℎ𝑜𝑠 ∗ [𝐴𝑀𝑃𝐾_𝑝𝑇172])	
+(𝑘𝑠𝑖𝑟𝑡 ∗ [𝑆𝐼𝑅𝑇] ∗ [𝐴𝑀𝑃𝐾])	
−([𝐴𝑐𝑡_𝑈𝐿𝐾1] ∗ [𝐴𝑀𝑃𝐾_𝑝𝑇172] ∗ 𝑘𝑈𝐾𝐴𝑃)	
 
+𝑘𝐴𝐾𝑇 ∗ ([𝐴𝑘𝑡_𝑝𝑇308] + [𝐴𝑘𝑡_𝑝𝑇308_𝑝𝑆473]) ∗ [𝐹𝑂𝑋𝑂_𝐴𝐶_𝑃] 	− 	𝑘𝐴𝑀𝑃𝐾 ∗ [𝐴𝑀𝑃𝐾_𝑝𝑇172] ∗ [𝐹𝑂𝑋𝑂_𝑑𝑒] 
 
 
+	𝑘𝐴𝑀𝑃𝐾 ∗ [𝐹𝑂𝑋𝑂_𝑑𝑒] ∗ [𝐴𝑀𝑃𝐾_𝑝𝑇172] 	− 	𝑘𝐴𝐾𝑇 ∗ ([𝐴𝑘𝑡_𝑝𝑇308_𝑝𝑆473] + [𝐴𝑘𝑡_𝑝𝑇308]) ∗ [𝐹𝑂𝑋𝑂_𝐴𝐶_𝑃]		
−	𝑘𝑆𝐼𝑅𝑇𝐹𝑂𝑋𝑂 ∗ [𝐹𝑂𝑋𝑂_𝐴𝐶_𝑃] ∗ [𝑆𝐼𝑅𝑇] 	+ 	𝑘𝐶𝐵𝑝 ∗ [𝐹𝑂𝑋𝑂_𝑃] ∗ [𝐶𝐵𝑃]	
 
+𝑘𝑆𝐼𝑅𝑇𝐹𝑂𝑋𝑂 ∗ [𝐹𝑂𝑋𝑂_𝐴𝐶_𝑃] ∗ [𝑆𝐼𝑅𝑇] 	− 	𝑘𝐶𝐵𝑝 ∗ [𝐹𝑂𝑋𝑂_𝑃] ∗ [𝐶𝐵𝑃] 
 
+	𝑘𝑑𝑛 ∗ [	𝐴𝐶_𝑃𝐺𝐶1𝛼] 
−
𝑉𝑠𝑝𝑔𝑐 ∗ 	𝑃𝐺𝐶1𝛼 ∗ 𝑆𝐼𝑅𝑇




𝑉𝑠𝑝𝑔𝑐 ∗ 	𝑃𝐺𝐶1𝛼 ∗ 𝑆𝐼𝑅𝑇









































−𝑘10 ∗ [𝑈𝐿𝐾1] ∗ [𝐴𝑀𝑃𝐾_𝑝𝑇172] 	+ 	𝑘𝑈𝐿𝐾𝑑 ∗ [𝐴𝑐𝑡_𝑈𝐿𝐾1] 	+ 	𝐾𝑈𝐿𝐾𝑀 ∗ [𝐴𝑐𝑡_𝑈𝐿𝐾1] ∗ [𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448] 
 
𝑘10 ∗ [𝑈𝐿𝐾1] ∗ [𝐴𝑀𝑃𝐾_𝑝𝑇172] 	− 	𝑘𝑈𝐿𝐾𝑑 ∗ [𝐴𝑐𝑡_𝑈𝐿𝐾1] 	− 	𝐾𝑈𝐿𝐾𝑀 ∗ [𝐴𝑐𝑡_𝑈𝐿𝐾1] ∗ [𝑚𝑇𝑂𝑅𝐶1_𝑝𝑆2448] 
 
(−(𝑁𝐴𝑀𝑖𝑚𝑝𝑜𝑟𝑡) 	+ 	0.9625 ∗ (𝑁𝐴𝑀𝑖𝑚𝑝𝑜𝑟𝑡) 	+	(𝑁𝑎𝑚_𝑢𝑝𝑡𝑎𝑘𝑒)) 
 
 
(1/𝑁𝑎𝑚𝑃𝑇_𝑐𝑜𝑚𝑝𝑎𝑟𝑡𝑚𝑒𝑛𝑡	 ∗ 	(𝑁𝐴𝐷_𝑏𝑖𝑛𝑑𝑖𝑛𝑔)) 
 
 
(1/𝑁𝑎𝑚𝑃𝑇_𝑐𝑜𝑚𝑝𝑎𝑟𝑡𝑚𝑒𝑛𝑡	 ∗ 	((𝑁𝑇5_𝑁𝑀𝑁)	−	(𝑃𝑁𝑃_𝑁𝑅)	−	(𝑁𝑅_𝑒𝑓𝑓𝑙𝑢𝑥) 	−	(𝑁𝑅𝐾1_𝑁𝑀𝑁))) 
 
 
(1/𝑁𝑎𝑚𝑃𝑇_𝑐𝑜𝑚𝑝𝑎𝑟𝑡𝑚𝑒𝑛𝑡	 ∗ 	((𝑁𝑀𝑁𝐴𝑇1_𝑁𝑎𝑀𝑁)	−	(𝑁𝐴𝐷𝑆))) 
 
(1/𝑁𝑎𝑚𝑃𝑇_𝑐𝑜𝑚𝑝𝑎𝑟𝑡𝑚𝑒𝑛𝑡	 ∗ 	 (−(𝑁𝑀𝑁_𝑒𝑓𝑓𝑙𝑢𝑥) 	− 	(𝑁𝑀𝑁𝐴𝑇1_𝑁𝑀𝑁)	−	(𝑁𝑇5_𝑁𝑀𝑁)	+	(𝑁𝐴𝑀𝑃𝑇) 	+ 	(𝑁𝑅𝐾1_𝑁𝑀𝑁))) 
 
(1/𝑁𝑎𝑚𝑃𝑇_𝑐𝑜𝑚𝑝𝑎𝑟𝑡𝑚𝑒𝑛𝑡	 ∗ 	(−(𝑁𝐴𝑃𝑅𝑇)	+	(𝑁𝐴𝐷𝐴)	−	(𝑁𝐴_𝑒𝑓𝑓𝑙𝑢𝑥) 	+	(𝑃𝑁𝑃_𝑁𝐴𝑅))) 
 
(1/𝑁𝑎𝑚𝑃𝑇_𝑐𝑜𝑚𝑝𝑎𝑟𝑡𝑚𝑒𝑛𝑡	 ∗ 	((𝑁𝐴𝑃𝑅𝑇)	−	(𝑁𝑀𝑁𝐴𝑇1_𝑁𝑎𝑀𝑁)	−	(𝑁𝑇5_𝑁𝑎𝑀𝑁)	+	(𝑁𝑅𝐾1_𝑁𝑎𝑀𝑁))) 
 
(1/𝑁𝑎𝑚𝑃𝑇_𝑐𝑜𝑚𝑝𝑎𝑟𝑡𝑚𝑒𝑛𝑡	 ∗ 	((𝑃𝑁𝑃_𝑁𝑅)	−	(𝑁𝑁𝑀𝑇)	−	(𝑁𝑎𝑚_𝑒𝑓𝑓𝑙𝑢𝑥) 	+	(𝑆𝐼𝑅𝑇)	+		





































(1/𝑁𝑎𝑚𝑃𝑇_𝑐𝑜𝑚𝑝𝑎𝑟𝑡𝑚𝑒𝑛𝑡	 ∗ 	((𝑁𝑇5_𝑁𝑎𝑀𝑁)	−	(𝑁𝐴𝑅_𝑒𝑓𝑓𝑙𝑢𝑥) 	−	(𝑁𝑅𝐾1_𝑁𝑎𝑀𝑁)	−	(𝑃𝑁𝑃_𝑁𝐴𝑅))) 
 
(𝑁𝑎𝑚𝑃𝑇_𝑐𝑜𝑚𝑝𝑎𝑟𝑡𝑚𝑒𝑛𝑡	 ∗ 	𝑐𝑒𝑙𝑙𝑑𝑖𝑣𝑖𝑠𝑖𝑜𝑛_𝑟𝑎𝑡𝑒_𝑁𝑎𝑚𝑃𝑇_𝑐𝑜𝑚𝑝𝑎𝑟𝑡𝑚𝑒𝑛𝑡	 ∗ 	𝑁𝑀𝑁) 
     

𝑁𝑎𝑚𝑃𝑇_	𝑐𝑜𝑚𝑝𝑎𝑟𝑡𝑚𝑒𝑛𝑡 ∗ 𝑁𝐴𝑃𝑅𝑇_𝐸_𝑇 ∗ 	𝑁𝐴𝑃𝑅𝑇_𝑡𝑢𝑟𝑛𝑜𝑣𝑣𝑒𝑟 ∗ 	𝑁𝐴	 ∗ 	𝐴𝑇𝑃 ∗ 𝑁𝐴𝑃𝑅𝑇_𝑠𝑐𝑎𝑙𝑖𝑛𝑔
𝑁𝐴𝑃𝑅𝑇_𝐾𝑚 + 	𝑁𝐴  
      
𝑁𝑎𝑚𝑃𝑇_𝑐𝑜𝑚𝑝𝑎𝑟𝑡𝑚𝑒𝑛𝑡	 ∗ 	(𝐸𝑇𝑁𝑀𝑁𝐴𝑇	 ∗ 	𝑁𝑀𝑁𝐴𝑇1_𝑁𝑀𝑁_𝑠𝑐𝑎𝑙𝑖𝑛𝑔	 ∗
	«𝑁𝑀𝑁𝐴𝑇_𝑁𝑀𝑁_𝑘𝑐𝑎𝑡_𝐴 ∗ 𝑁𝑀𝑁𝑁𝑀𝑁𝐴𝑇_𝑁𝑀𝑁_𝑘𝑚_𝐴¬– «𝑁𝑀𝑁𝐴𝑇1_𝑁𝑀𝑁_𝑘𝑐𝑎𝑡_𝑃𝐴 ∗
𝑁𝐴𝐷
𝑁𝑀𝑁𝐴𝑇1_𝑁𝑀𝑁_𝑘𝑚_𝑃𝐴¬









𝑁𝑎𝑚𝑃𝑇_𝑐𝑜𝑚𝑝𝑎𝑟𝑡𝑚𝑒𝑛𝑡	 ∗ 	 (𝐸𝑇𝑁𝑀𝑁𝐴𝑇	 ∗ 	𝑁𝑀𝑁𝐴𝑇1_𝑁𝑎𝑀𝑁_𝑠𝑐𝑎𝑙𝑖𝑛𝑔	 ∗ 	;𝑁𝑀𝑁𝐴𝑇1_𝑁𝑎𝑀𝑁_𝑘𝑐𝑎𝑡_𝐴 ∗ 𝑁𝑎𝑀𝑁𝑁𝑀𝑁𝐴𝑇1_𝑁𝑎𝑀𝑁_𝐾𝑚_𝐴 		− 	
𝑁𝑀𝑁𝐴𝑇1_𝑁𝐴𝑀𝑁_𝑘𝑐𝑎𝑡_𝑃𝐴 ∗ 𝑁𝑎𝐴𝐷
𝑁𝑀𝑁𝐴𝑇1_𝑁𝑎𝑀𝑁_𝐾𝑚_𝑃𝐴 @
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Table A1. Parameter values for the metabolic signaling pathway model described in Chapter 2, and used 
in the above model equations.  
Rate parameter names Values 
compartment_Cell 1 
par_IRS_phos_by_Amino_Acids 0.0331672 (min^-1) 
par_AMPK_T172_phos_by_Amino_Acids 17.6284 (min^-1) 
par_mTORC2_S2481_phos_by_Amino_Acids 0.0268658 (min^-1) 
par_IR_beta_phos_by_Insulin 0.0203796 (min^-1) 
par_IR_beta_pY1146_dephos 0.493514 (min^-1) 
par_IR_beta_ready 323.611 (min^-1) 
par_IRS_phos_by_IR_beta_pY1146 2.11894 (min^-1) 
par_IRS_p_phos_by_p70_S6K_pT229_pT389 0.3388 (min^-1) 
par_IRS_phos_by_p70_S6K_pT229_pT389 0.08637 (min^-1) 
 
81 
par_IRS_pS636_turnover 25 (min^-1) 
par_AMPK_T172_phos 0.490602 (min^-1) 
par_AMPK_pT172_dephos 165.704 (min^-1) 
par_Akt_S473_phos_by_mTORC2_pS2481_first 0.0000131992 (min^-1) 
par_Akt_S473_phos_by_mTORC2_pS2481_second 0.159093 (min^-1) 
par_Akt_T308_phos_by_PI3K_p_PDK1_first 7.47437 (min^-1) 
par_Akt_T308_phos_by_PI3K_p_PDK1_second 7.47345 (min^-1) 
par_Akt_pT308_dephos_first 88.9654 (min^-1) 
par_Akt_pT308_dephos_second 88.9639 (min^-1) 
par_Akt_pS473_dephos_first 0.376999 (min^-1) 
par_Akt_pS473_dephos_second 0.380005 (min^-1) 
par_TSC1_TSC2_S1387_phos_by_AMPK_pT172 0.00175772 (min^-1) 
par_TSC1_TSC2_T1462_phos_by_Akt_pT308 1.52417 (min^-1) 
par_TSC1_TSC2_pS1387_dephos 0.25319 (min^-1) 
par_TSC1_TSC2_pT1462_dephos 147.239 (min^-1) 
par_mTORC1_pS2448_dephos_by_TSC1_TSC2 0.00869774 (min^-1) 
par_mTORC1_S2448_activation_by_Amino_Acids 0.0156992 (min^-1) 
par_mTORC2_pS2481_dephos 1.42511 (min^-1) 
par_mTORC2_S2481_phos_by_PI3K_variant_p 0.120736 (min^-1) 
par_p70_S6K_T229_phos_by_PI3K_p_PDK1_first 0.0133521 (min^-1) 
par_p70_S6K_T229_phos_by_PI3K_p_PDK1_second 1.00E-06 
par_p70_S6K_T389_phos_by_mTORC1_pS2448_first 0.00261 (min^-1) 
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par_p70_S6K_T389_phos_by_mTORC1_pS2448_second 0.11072089 (min^-1) 
par_p70_S6K_pT229_dephos_first 1.00E-06 
par_p70_S6K_pT229_dephos_second 0.159201353 (min^-1) 
par_p70_S6K_pT389_dephos_first 1.10036056 (min^-1) 
par_p70_S6K_pT389_dephos_second 1.1021526 (min^-1) 
par_PRAS40_S183_phos_by_mTORC1_pS2448_first 0.15881 (min^-1) 
par_PRAS40_S183_phos_by_mTORC1_pS2448_second 0.0683009 (min^-1) 
par_PRAS40_T246_phos_by_Akt_pT308_first 0.279344 (min^-1) 
par_PRAS40_T246_phos_by_Akt_pT308_second 0.279401 (min^-1) 
par_PRAS40_pS183_dephos_first 1.8706 (min^-1) 
par_PRAS40_pS183_dephos_second 1.88453 (min^-1) 
par_PRAS40_pT246_dephos_first 11.8759 (min^-1) 
par_PRAS40_pT246_dephos_second 11.876 (min^-1) 
par_PI3K_p_PDK1_dephos 0.18913343 (min^-1)  
par_PI3K_PDK1_phos_by_IRS_p 0.0001872267 (min^-1) 

















ksirt 5*2.0e7 1/s 
kAKT 0.5 (min^-1) 
kAMPK 0.5 (min^-1) 
kSIRTFOXO 0.1 (min^-1) 
AVG_CBP 0.1 mM 
Vopgc 0.000046(mM) 
Vspgc 0.000142 (mM) 
kAPGC 0.007578 (mM) 
Vdpgc 0.000388 (mM) 
kdpgc 0.003299 (mM) 
kdn 0.0012 (min^-1) 
k10  0.000166 ((nM*min)^-1) 
kULKd  0.00169 ((nM*min)^-1) 
KULKM  0.000158 ((nM*min)^-1) 
argeninie vmax 0.5470 mmol.min^-1 
mTORC1_L_vmax  1.5 mol.min^-1. 
leucine_a    100 
Km_NamPRT  0.005 mM 
Kcat_NamPRT  0.462 (min^-1) 
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ETNMNAT  10 
Initial_for_cell_devision_all  2.80E-05 
NAPRT_E_T  10 
NAPRT_turnover  3.3 
NAPRT_scaling  0.001 
NAPRT_Km  0.00015 mM 
NMNAT1_NMN_scaling  0.001 
NMNAT1_NMN_kcat_A  32281 (min^-1) 
NMNAT1_NMN_Km_A  0.0223 mM 
NMNAT1_NMN_kcat_PA  77401 (min^-1) 
NMNAT1_NMN_Km_PA  0.059 mM 
NMNAT1_NMN_Km_B  0.0677 mM 
NMNAT1_NMN_Km_PB  0.502 mM 
NMNAT1_NaMN_scaling  0.001 
NMNAT1_NaMN_kcat_A  25741 (min^-1) 
NMNAT1_NaMN_Km_A  0.0677 mM 
NMNAT1_NaMN_kcat_PA  62281 (min^-1) 
NMNAT1_NaMN_Km_PA  0.502 mM 
NMNAT1_NaMN_Km_B  22.3 mM 
NMNAT1_NaMN_Km_PB  0.059 mM 
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NADS_E_T  10 
NADS_turnover  21 
NADS_scaling  0.001 
NADS_Km  0.19 mM 
NT5_NMN_ET  10 
NT5_NMN_scaling  0.001 
NT5_NMN_kcat  301 (min^-1) 
NT5_NMN_Km  5 mM 
PNP_NR_E_T  10 
PNP_NR_turnover  40 
PNP_NR_scaling  0.001 
PNP_NR_Km  1.48 mM 
NNMT_ET  10 
NNMT_scaling  0.001 
NNMT_Kcat  4861 (min^-1) 
NNMT_Ki  0.06 mM 
Kma  0.0018 mM 
Kmb  0.4 mM 
NT5_NaMN_ET  10 
NT5_NaMN_scaling  0.001 
NT5_NaMN_kcat  1681 (min^-1) 
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NT5_NaMN_Km  3.5 mM 
SIRT_ET  10 
SIRT_scaling  0.001 
SIRT_Kcat  40.21 (min^-1) 
SIRT_Km  0.029 mM 
SIRT_Ki  0.06 mM 
NAD_consumption_without_Nam_inhibition_ET  10 
NAD_consumption_without_Nam_inhibition_scaling  0.001 
NAD_consumption_without_Nam_inhibition_kcat  1 (min^-1) 
NAD_consumption_without_Nam_inhibition_Km  1 mM 
NADA_ET  0 
NADA_scaling  0.001 
NADA_Kcat  41.4 (min^-1) 
NADA_Km  0.009 mM 
NADA_Ki  0.1 mM 
NAMPT_ET  400 
NAMPT_scaling  0.001 
NAMPT_Ki  0.0021 mM 
NAD_binding_k1  6000 (min^-1) 
NAD_binding_k2  600 (min^-1) 
NRK1_NaMN_ET  10 
NRK1_NaMN_scaling  0.001 
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NRK1_NaMN_kcat  13.8 (min^-1) 
NRK1_NaMN_Km  0.0034 mM 
PNP_NAR_E_T  10 
PNP_NAR_turnover  40 
PNP_NAR_scaling  0.001 
PNP_NAR_Km  1.48 mM 
NRK1_NMN_ET  10 
NRK1_NMN_scaling  0.001 
NRK1_NMN_kcat  13.8 (min^-1) 
NRK1_NMN_Km  0.0034 mM 
v  0.00001 mM/s 
Cytosol   1 L 
NamPT_compartment  0.001 L 
celldivision_rate_NamPT_compartment   0.0017  mM/min 
Gln  1 mM 
DNA_damage  1 mM 
DNA_ADPR  1 mM 
H3_ac  1 mM 
H3_deac  1 mM 
Glu  1 mM  
Pi   1 mM 
methyl_NAM   0.01 mM 
H2O  1 mM 
PPi  0.012 mM 
AMP  1 mM 
ADP  1 mM 
 
88 
SAM  0.08 mM 
SAH  1 mM 
PRPP  1 mM 
ATP  1 mM 





A.2 Model equations and parameters for circadian clock model 
Below is a complete list of equations used in the metabolic signaling pathway model described in Chapter 
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𝟏 +  [CB]𝑲𝒂_𝒓𝒆𝒗_𝒄𝒃 ∗ (𝟏 + Act_SIRT)
𝒉𝒊𝒍𝒍_𝒓𝒆𝒗_𝒄𝒃














𝑽𝒎𝒂𝒙_𝒓𝒐𝒓 ∗	𝟏 + 𝒇𝒐𝒍𝒅_𝒓𝒐𝒓 ∗	 [CB]𝑲𝒂_𝒓𝒐𝒓_𝒄𝒃 ∗ (𝟏 + Act_SIRT)
𝒉𝒊𝒍𝒍_𝒓𝒐𝒓_𝒑𝒄

𝟏 +  [CB]𝑲𝒂_𝒓𝒐𝒓_𝒑𝒄 ∗ (𝟏 + Act_SIRT)
𝒉𝒊𝒍𝒍_𝒓𝒐𝒓_𝒄𝒃


























































𝑽𝒎𝒂𝒙_𝒃𝒎𝒂𝒍 ∗	𝟏 + 𝒇𝒐𝒍𝒅_𝒃𝒎𝒂𝒍 ∗ (𝟏 + Act_PGC1a) ∗	 [Prot_ror]𝑲𝒂_𝒃𝒎𝒂𝒍_𝒓𝒐𝒓
𝒉𝒊𝒍𝒍_𝒃𝒎𝒂𝒍_𝒓𝒐𝒓











−𝒅𝒑_𝒑𝒆𝒓 ∗ (𝟏	 + 	𝒎_𝒑𝒆𝒓_𝒔𝒊𝒓𝒕 ∗ Act_SIRT + 	𝒎_𝒑𝒆𝒓_𝒂𝒎𝒑𝒌 ∗ Act_AMPK)	
∗ 	 [Prot_per]		
+	𝒌𝒑_𝒑𝒆𝒓 ∗ [per]	
−(𝒌𝒂𝒔𝒔_𝒑𝒄	 ∗ 	 [Prot_cry] 	∗ [Prot_per] − 𝒌𝒅𝒊𝒔𝒔_𝒑𝒄 ∗ [PC]	) 
 
 
−𝒅𝒑_𝒄𝒓𝒚 ∗ (𝟏	 + 	𝒎_𝒄𝒓𝒚_𝒂𝒎𝒑𝒌 ∗ 𝑨𝒄𝒕_𝑨𝑴𝑷𝑲)	∗ 	 [Prot_cry]		
+	𝒌𝒑_𝒑𝒆𝒓 ∗ [cry]	













−(𝒌𝒂𝒔𝒔_𝒄𝒃 ∗	 [Prot_bmal] 	− 𝒌𝒅𝒊𝒔𝒔𝒄𝒃 ∗ [CB]	)	
+(𝒑𝒂𝒓_𝒎𝑻𝑶𝑹𝑪𝟏_𝒃𝒎𝒂𝒍	 ∗ 	 [𝑷𝒓𝒐𝒕_𝒃𝒎𝒂𝒍] ∗ [𝒎𝑻𝑶𝑹𝑪𝟏]) 
 
 
+(𝒌𝒂𝒔𝒔_𝒑𝒄	 ∗ 	 [Prot_cry] 	∗ [Prot_per] − 𝒌𝒅𝒊𝒔𝒔_𝒑𝒄 ∗ [PC]	) 
−𝒅𝒑_𝒑𝒄 ∗ [PC] 
 
 
+(𝒌𝒂𝒔𝒔_𝒄𝒃	 ∗ 	[Prot_bmal] 	− 𝒌𝒅𝒊𝒔𝒔_𝒄𝒃 ∗ [CB]	) 
−𝒅𝒑_𝒄𝒃 ∗ [CB]	








𝑽𝒎𝒂𝒙_𝒏𝒂𝒎𝒑𝒕 ∗	𝟏 + 𝒇𝒐𝒍𝒅_𝒏𝒂𝒎𝒑𝒕 ∗	 [CB]𝑲𝒂_𝒏𝒂𝒎𝒑𝒕_𝒄𝒃 ∗ (𝟏 + Act_SIRT)
𝒉𝒊𝒍𝒍_𝒏𝒂𝒎𝒑𝒕_𝒄𝒃

𝟏 +  [CB]𝑲𝒂_𝒏𝒂𝒎𝒑𝒕_𝒄𝒃 ∗ (𝟏 + Act_SIRT)
𝒉𝒊𝒍𝒍_𝒏𝒂𝒎𝒑𝒕_𝒄𝒃











𝟏 +𝒎_𝒏𝒂𝒎𝒑𝒕_𝒂𝒎𝒑𝒌	 ∗ 	Act_AMPK 






















𝒅_𝒏𝒂𝒅	 ∗ ([NAD] −𝑵𝑨𝑫_𝒃𝒂𝒔𝒂𝒍)
𝑲𝒏𝒂𝒅+ [NAD] −𝑵𝑨𝑫_𝒃𝒂𝒔𝒂𝒍  
+
𝑽𝒎𝒂𝒙_𝒏𝒂𝒅 ∗ [Prot_nampt] 	∗ ([NAD] −𝑵𝑨𝑫_𝒃𝒂𝒔𝒂𝒍)








𝑽𝒎𝒂𝒙_𝒅𝒃𝒑 ∗	𝟏 + 𝒇𝒐𝒍𝒅_𝒅𝒃𝒑 ∗	 [CB]𝑲𝒂_𝒅𝒃𝒑_𝒄𝒃 ∗ (𝟏 + Act_SIRT)
𝒉𝒊𝒍𝒍_𝒅𝒃𝒑_𝒄𝒃

𝟏 +  [CB]𝑲𝒂_𝒅𝒃𝒑_𝒄𝒃 ∗ (𝟏 + Act_SIRT)
𝒉𝒊𝒍𝒍_𝒅𝒃𝒑_𝒄𝒃









𝑪𝒔𝒊𝒓𝒕 ∗ 𝑽𝒔𝒊𝒓𝒕 ∗ [NAD]
𝑲𝒔𝒊𝒓𝒕 + [NAD]  
 
𝑪𝒑𝒈𝒄𝟏 ∗ 𝑽𝒑𝒈 ∗ Act_AMPK ∗ Act_SIRT ∗ Prot_TGC1a







Table A2. Parameter values for the metabolic circadian clock model described in Chapter 4, and used in 
the above model equations.  
Symbol Description Value 
𝑝𝑎𝑟_𝑏𝑚𝑎𝑙_𝑚𝑇𝑂𝑅𝐶1 Inhibitory effect of BMAL1 on mTORC1 0.0118  
𝑝𝑎𝑟_𝑝𝑒𝑟_𝑚𝑇𝑂𝑅𝐶1 Inhibitory effect of PER2 on mTORC1 0.0104  
𝑝𝑎𝑟_𝑚𝑇𝑂𝑅𝐶1_𝑏𝑚𝑎𝑙 Activating effect of mTORC1 on BMAL1 0.0104  
𝑝𝑎𝑟_𝑚𝑇𝑂𝑅𝐶1_𝑐𝑏 Inhibitory effect of mTORC1 on CLOCK-BMAL1 0.0261  
𝑘𝑝_𝑏𝑚𝑎𝑙 Translation rate constant from Bmal1 mRNA to BMAL1 protein 0.5405 
𝑑𝑝_𝑏𝑚𝑎𝑙 Degradation rate of BMAL1 protein 0.2252 
𝑘𝑎𝑠𝑠_𝑐𝑏 Association rate constant of CLOCK-BMAL! complex 0.0151 
𝑘𝑑𝑖𝑠𝑠_𝑐𝑏 Disassociation rate constant of CLOCK-BMAL! complex 0.0066 
𝑑_𝑐𝑏 Degradation rate of CLOCK-BMAL1  0.0849 
𝑘𝑝_𝑝𝑒𝑟 Translation rate constant from Per2 mRNA to PER2 protein 3.9968 
𝑑𝑝_𝑝𝑒𝑟 Degradation rate of PER2 protein 56.1535 
𝑑𝑚_𝑝𝑒𝑟 Degradation rate of Per2 mRNA 0.3005 
𝑉𝑚𝑎𝑥_𝑝𝑒𝑟 Generation rate constant of Per1 mRNA 0.8032 
𝑘𝑝_𝑐𝑟𝑦 Translation rate constant from Cry1 mRNA to CRY1 protein 14.0871 
 
91 
𝑑𝑝_𝑐𝑟𝑦 Degradation rate of CRY1 protein 0.6536 
𝑘𝑎𝑠𝑠_𝑝𝑐 Association rate constant of PER-CRY complex 13.2884 
𝑘𝑑𝑖𝑠𝑠_𝑝𝑐 disassociation rate constant of PER-CRY complex 0.0261 
𝑘𝑝_𝑟𝑒𝑣 Translation rate constant from Rev-Erb mRNA to REV-ERB protein 0.0641 
𝑘𝑝_𝑟𝑜𝑟 Translation rate constant from Ror mRNA to ROR protein 0.3677 
 
 
